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Myosiny jsou proteiny, které přeměňují chemickou energii uloženou v ATP na 
mechanickou sílu, která se aplikuje na vlákna aktinu. Jaderný myosin 1 (NM1) byl první 
myosin detekován v jádře buňky. Spolu s jaderným aktinem hraje důležitou roli při 
transkripci DNA a remodelaci chromatinu. Nicméně, molekulární mechanismy funkce 
NM1 jsou zatím neznámé. K získání dalších poznatků o tomto molekulárním motoru jsme 
studovali expresi a distribuci NM1 v tkáních, mechanismus jeho jaderné lokalizace a také 
jeho další molekulární interakce. 
V první části byla studována exprese NM1 v různých tkáních myší. Bylo prokázáno, že 
NM1 se vyskytuje v buněčných jádrech všech myších tkání, přičemž do studia nebyly 
zahrnuty buňky v terminálním stádiu spermatogeneze. Kvantitativní PCR a western blot 
prokázaly, že exprese NM1 je různá v jednotlivých myších tkáních a nejvyšší je v plicích. 
NM1 je izoforma dříve objeveného myosinu 1c (Myo1c), který byl popsán nejprve jako 
protein cytosolový. Jediný známý rozdíl mezi těmito dvěma proteiny je přítomnost 16 
aminokyselin na N-konci NM1. V další části byl proto studován vliv NM1 domén, včetně 
N-koncového peptidu, na subcelulární lokalizaci tohoto proteinu. Zjistili jsme, že N-
koncový peptid NM1 není nezbytný pro jeho vstup do jádra. Jaderný lokalizační signál 
jsme objevili v doméně NM1 která také váže lehký řetězec, kalmodulin. Tato doména je 
přítomna také v "cytoplasmatické" isoformě, v proteinu Myo1c. Potvrdili jsme přítomnost 
obou izoforem v buněčném jádře. Použitím polyklonálních protilátek proti N-konci NM1 a 
monoklonální protilátky proti ocasu NM1/Myo1c bylo ukázáno, že endogenní NM1 a 
Myo1c kolokalizují ve zvýšené míře v jádře a na plazmatické membráně. Nakonec jsme 
použitím techniky ko-imunoprecipitace identifikovali nové interakční partnery NM1 
zejména aktin- a fosfolipid-vázajících proteiny. Zajímavé je, že některé z identifikovaných 
proteinů byly rovněž popsány v komplexu s Myo1c. Závěrem vyslovujeme hypotézu, že 
NM1 a Myo1c by mohly být stejné funkční varianty jednoho genu. 
V této práci jsou prezentovány výsledky, které zvýšily naše znalosti o expresi a lokalizaci 
NM1 v tkáních, mechanismu jeho jaderné lokalizace a jeho molekulárních interakcí. 
Nejzajímavějším výsledkem je, že NM1 je více podobný Myo1c, než bylo původně 
předpokládáno. Proto cílem dalších experimentů bude ověřit, zda NM1 a Myo1c jsou 




Myosins are proteins that convert chemical energy stored in ATP into mechanical force 
that is applied on an actin filament. Nuclear myosin 1 (NM1) was the first myosin detected 
in the cell nucleus. Together with nuclear actin they were shown to play important roles in 
DNA transcription and chromatin remodeling. However, the molecular details of the NM1 
functions are largely unknown. To expand our knowledge about this molecular motor we 
studied tissue expression, mechanism of nuclear localization and molecular interactions of 
this myosin motor. 
In the first part we examined the expression pattern of NM1 in various mouse tissues. We 
demonstrated that NM1 is present in cell nuclei of all mouse tissues examined except for 
cells in terminal stages of spermatogenesis. Quantitative PCR and western blots 
demonstrated that the expression of NM1 in tissues varies, with the highest levels in the 
lungs. NM1 is a nuclear isoform of earlier identified myosin 1c (Myo1c), which was 
described initially as a cytosolic, and plasma membrane associated protein. The only 
known difference between these two proteins was the presence of additional 16 amino 
acids at the N-terminus of NM1. Next we focused on the influence of NM1 domains, 
including the N-terminus, on the subcellular localization of this protein. We found out that 
N-terminus is not required for nuclear entry. Surprisingly, we found a nuclear localization 
sequence placed within calmodulin-binding motif of NM1. This sequence is also present in 
the “cytoplasmic” Myo1c protein. We confirmed the presence of both isoforms in the 
nucleus. The notion that overexpressed NM1 and Myo1c could localize to the cell nucleus 
prompted us to inspect their colocalization in cells and tissues. Using polyclonal antibodies 
toward the N-terminus of NM1 and a monoclonal antibody against the tail domain we 
found that endogenous NM1 and Myo1c colocalize to a high extend in nucleus and at the 
plasma membrane. Finally, we looked for new interaction partners of NM1 using co-
immunoprecipitation. We found set of actin- and phospholipid- binding proteins as the 
proteins that co-purified from the cell extracts with NM1. Interestingly, some of the 
identified proteins were also found in complex with Myo1c. We hypothesized that NM1 
and Myo1c could be functionally similar transcript variants of the same gene. 
The most intriguing result is that NM1 is more similar to Myo1c than previously imagined. 
Therefore one of the most interesting future questions would be to verify whether NM1 
and Myo1c are functionally identical. Naturally, this requires further experiments. 
3. GENERAL INTRODUCTION  
3.1. The myosin superfamily  
Myosins are unique proteins that have the ability to transform free chemical energy stored 
in ATP into mechanical force. They are best known as engines that power the muscle 
contraction. In addition to “conventional” muscle myosin, there is a whole family of other 
myosins called “unconventional” myosins. The first unconventional myosin was isolated 
from Acanthamoeba (Pollard and Korn, 1973). This myosin displayed differences from the 
muscle myosin in being of lower molecular weight and having only single motor domain. 
It was named myosin-I. Since that time many other unconventional myosins (termed 
myosin III – XVII) have been isolated and the family became larger (Figure I). 
Importantly, in organisms the expression of these motor proteins is not restricted to muscle 












Figure I.  Myosin superfamily. 
3.2. The myosin working cycle  
Every myosin is in fact an ATPase that binds ATP, cleaves it into ADP and inorganic 
phosphate (Pi) and releases the products of cleavage in a stepwise manner. This cycle is 
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many fold faster in the presence of actin, therefore myosins are actin-activated ATPases. 
During the ATPase cycle the myosin head undergoes also substantial conformational 
changes that in turn alter its affinity for actin as a result, myosin cycles between strong and 
weak actin binding states. The nucleotide-free head binds strongly to actin. This state is 
called rigor (from rigor mortis - stiffness of the dead body). The actin-myosin crossbridge 
is dissociated by binding of ATP to the head of myosin. Upon detachment from actin, the 
head cleaves ATP into ADP*Pi and myosin recocks itself for the power stroke. At this 
state it binds stereospecifically between two adjacent actins in the actin filament. 
Concomitantly with the release of Pi a series of conformational changes cause swinging of 
so called converter domain that results in movement of the tail. During this state myosin 
generates force (Geeves and Holmes, 1999), ADP is released from the head and the 







Figure II. The myosin ATPase cycle 
3.3. Biochemical characteristics of class I myosins 
The lifetimes of strong and weak actin binding states together with duty ratio (fraction of 
total ATPase cycle where myosin is tightly bound to actin) are important characteristics 
describing the motile properties of a given myosin. Class I myosins are cleaving ATP 
slowly and spend small fractions of their ATPase cycle tightly bound to actin. Another 
characteristic of molecular motors is the processivity; defined by the number of ATPase 
cycles that the motor spends tightly associated with its track. As can be already deduced 
from the myosin ATPase cycle, a single molecule of myosin is non-processive because it 
requires detachment from the actin track in order to continue in ATPase cycle. Processivity 
is thus arranged by association of myosin molecules into large arrays. Subclass 2 of 
myosin I´s contains a short tail and is therefore unable to dimerize. There must be at least 
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50 molecules of these myosins attached to the cargo and actin filament at the same time in 
order to achieve processivity (O'Connell et al., 2007). 
In conclusion, myosin I family members are monomeric, non-processive, slow rate and 
low duty ratio motors. 
3.4. Structure of class I myosins  
Phylogenetically, myosin I class could be divided into two subclasses. Subclass I members 
have long tails consisting of tail homology 1 (TH1), tail homology II (TH2) and SH3 
domains. On the other hand subclass II has only short tail containing TH1 domain (Figure 
III). Nuclear myosin 1 (NM1) belongs to the subclass II. Based on their motor domain 
sequences, the class I myosins can be further sub-divided into two subclasess. In 
vertebrates, the long tailed (Myo1E) forms the subclass I, and the short tailed (Myo1A, 




Figure III. Domain organization of class I myosins  
3.4.1. The head domain 
The ATPase cycle of subclass 2 myosins has an interesting property which results in a 
power stroke that has two steps (Veigel et al., 1999; Batters et al., 2004a). Rapid and large 
displacement of lever arm is followed by an additional swinging of the lever arm that leads 
to smaller displacement. Optical trap measurements revealed that the second step is 
accompanied by ADP release. Interestingly, in the presence of opposing force (i.e applied 
against the power stroke direction) the ADP is trapped in the head and myosin stays tightly 
bound to actin. The power stroke is finished only when the strain is relieved and the actin 
filament moves in the direction of power stroke. This property could be used in 
maintaining a sustained tension (Batters et al., 2004b) or a directional movement. If the 
mechanical load is applied on myosin I, it can switch from a low to a high duty ratio motor 
(Laakso et al., 2008), which means that it stays bound longer to the actin filament. 
Subclass II of myosin I molecules do not have the ability to “walk” along the actin 





they can support unidirectional movement of a load that would be otherwise moved back 
and forth by diffusion. This knowledge has led to a model where myosin I molecules 
support the unidirectional movement of their cargoes acting as Brownian ratchets 
(Nambiar et al., 2010).  
3.4.2. The neck domain 
Neck domain (also the regulatory domain or the light chain binding domain) of myosins is 
continuation of the converter domain that transmits the movements produced by 
conformational changes in the head further to the tail. It consists of helical sequences that 
are bound by small proteins called the light chains. The function of light chains is to 
stabilize the lever arm of myosin and ensure that mechanical force is transmitted to the tail. 
In most class I myosins the light chains are calmodulins that bind to so called IQ motifs. 
These are short peptides (~25 residues in length), containing isoleucine and glutamine 
residues. The consensus motif is IQXXXRGXXXR, where residues X vary and may to a 
great extend modify the mechanism of calmodulin binding (Houdusse et al., 2006). Myosin 
I class members have 1-6 IQ motifs and it is believed that the length of neck determines 
the size of displacement steps (Kohler et al., 2003). Crystal structure of first two IQ motifs 
of myosin V in complex with calmodulin revealed that the calmodulin binds neck in 
calcium-free state wrapping around the IQ motif with its C-terminal lobe (Houdusse et al., 
2006). Binding of calcium to calmodulin weakens the binding of calmodulin to the neck 
which leads to dissociation of some calmodulin molecules from the tail (Manceva et al., 
2007). Besides binding calmodulins the IQ motifs of myosin 1c were shown direct its 
subcellular localization and binding to yet unknown receptors in the plasma membrane of 
mechanosensitive hair cells of the inner ear (Cyr et al., 2002). Discovering IQ-binding 
proteins will allow us to obtain better insight into the molecular functions of myosin-I. 
3.4.3. The tail domain 
The tail domain is the most divergent part of a myosin molecule that fundamentally 
influences its functions. Given the nature of their ATPase cycles all myosin motors are 
non-processive but the long tail with coiled-coil motif of class II members enables the 
bundling of many heads into one filament. This is increasing the probability of having 
more heads attached to the actin filament and executing power stroke while the others are 
just positioning themselves for another ATPase cycle. Only few unconventional myosins 
have the ability homodimerize via their tails (e.g. myosin V, myosin VI) and move along 
the actin filament processively.  Most tails of class I myosins contain specific binding sites 
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for cargoes. The tail of subclass II is short, basic and has the affinity toward the acidic 
phospholipids such as PIP2 (Tang et al., 2002; Hokanson and Ostap, 2006). Interestingly, 
the tail domain seems to adopt different conformations in response to calcium as shown by 
cryo-electron microscopy analysis of the Myo1a protein (Whittaker and Milligan, 1997). 
3.5. Regulation of myosin I motility 
Proposed mechanism of the regulation of myosin predicts that the light chains which bind 
the neck part, stabilize the lever arm of myosin, thus the force generated by head could be 
transmitted to the tail (Barylko et al., 2005). Both the ATPase activity and the myosin 
motility are influenced by calcium. Elevated Ca2+ levels stimulate the ATPase activity of 
myosin several times (Lieto-Trivedi and Coluccio, 2008). Although this might suggest that 
the motility is stimulated by calcium, the opposite is true. Micromolar concentration of free 
Ca2+  inhibited the movement of actin filaments in an actin-gliding assay (Zhu et al., 1998). 
This is because the calcium also causes dissociation of one calmodulin from the neck of 
myosin while the other changes the conformations. In agreement with the lever arm model, 
calmodulin dissociation from myosin weakens the lever arm and force generation is 
inhibited. At the present it is not clear which calmodulin dissociates from the neck of 
Myo1c as the first, but based on biochemical studies (Manceva et al., 2007), it was 
proposed that the first IQ in the vicinity of the head domain binds the Ca2+-calmodulin 
with the lowest affinity. Further in vivo studies supported this model by the fact that 
elevated calcium not only causes dissociation of calmodulin but also provokes 
phosphorylation of serine in the first IQ. Addition of phosphate group to the serine residue 
within the first IQ by casein kinase increases negative charge and results in electrostatic 
repelling of calmodulin. That leads to more stabile inactivation of the motility (Yip et al., 
2008) . Also protein kinase C was shown to be able to phosphorylate myosin I (Swanljung-
Collins and Collins, 1992; Williams and Coluccio, 1995) however, this modification did 
not influence the actin sliding. 
3.6. Discovery of NM1 
Nuclear myosin 1 (also Nuclear myosin 1 beta) was discovered accidentally in 1997 
(Nowak et al., 1997). The original intention of investigators was to prepare polyclonal 
antibody against a myosin 1 that was purified from bovine adrenal gland. Surprisingly, the 
affinity purified antibody against adrenal myosin 1 preparation had a strong 
immunoreactivity against the cell nucleus. It also recognized band on western blot with 
approximate molecular weight of 120 kDa. Similarly to other myosin I family members, 
the partially purified protein bound calmodulin, ATP and actin. In order to identify the 
recognized protein, 3T3 nuclear extracts were subjected to immunoprecipitation with the 
polyclonal sera. The mass spectrometric analysis of the immunopurified protein showed 
high homology to a member of the myosin 1 family, the Myo1c (myr2, myosin 1 beta) 
known to be associated with plasma membrane (Wagner et al., 1992). Interestingly, the 
micro-sequencing also revealed the presence additional 16 amino acids at the N-terminus 
of NM1. Affinity purified antibody generated against the N-terminal 16 amino acid peptide 
specifically labeled nuclei of different cell types. Due to the fact that this was the first 
myosin identified in the cell nucleus the protein was named Nuclear myosin 1 (NM1) 
(Pestic-Dragovich et al., 2000). 
3.7. NM1/Myo1c gene 
Human Myo1c gene is located at reverse strand of chromosome 17. Mouse myo1c is 
located at chromosome 11. Alternative start of transcription and splicing gives rise to two 
mRNAs (Scheme 1 and Figure IV) that differ in their 5’ ends (Pestic-Dragovich et al., 
2000). The NM1 mRNA contains an upstream start of translation that brings about the 
additional 16 amino acids that were found in protein by microsequencing. This additional 
start of translation is found in exon -1. The transcription of Myo1c gene starts more 
upstream in, and is the resulting mRNA containing exons -2 and 1, possibly due to 
alternative splicing. Downstream sequence of Myo1c and NM1 is essentially the same. The 



















Figure IV. Translation starts of NM1 and Myo1c (Pestic-Dragovich et al., 2000). 
3.8. Myo1c protein 
Myo1c was discovered independently by several investigators earlier than NM1 (Wagner 
et al., 1992; Gillespie et al., 1993; Zhu and Ikebe, 1994; Ruppert et al., 1995). Firstly, it 
was named based on the source tissue or animal (mammalian myosin 1beta, myr2 – rat 
brain, BAGMI-bovine adrenal gland myosin 1). After unification of the myosin 
nomenclature it is called Myosin 1c (Gillespie et al., 2001). 
Myo1c is a short-tailed class I unconventional myosin, unable to form dimers. The overall 
structure (Scheme 2) consists of the head domain (ATPase), the neck domain 
(transmission) and the short tail (binding cargoes). It binds directly ATP and actin via the 











The tail domain of Myo1c binds tightly and specifically to negatively charged lipids such 
as PIP2 in vivo and in vitro (Hokanson et al., 2006; Hokanson and Ostap, 2006). The 
energy of the PIP2-Myo1c bond is higher than is needed for extraction of the lipid from the 
bilayer (Pyrpassopoulos et al., 2010). Besides PIP2 there are also protein interaction 
partners that were shown to bind directly to myo1c tail.  
3.8.1. Cellular functions of Myo1c 
This protein shows wide expression in variety of rat tissues (Wagner et al., 1992; Ruppert 
et al., 1995). The molecular function of Myo1c had been studied thoroughly in number of 
different cell types and was mostly connected dynamic events at the cytoplasmic 
membrane. 
Perhaps the most extensively studied is the function of myo1c the process of hearing. The 
hair cells located in inner ear form the apparatus that is able to transform mechanical 
pulses into electrical ones. These impulses are processed by brain into perception of sound. 
Myo1c was observed in clusters along actin-rich protrusions emanating from the hair cell 
body (Garcia et al., 1998) with highest concentration at the tips of these so-called 
stereocilia. Stereociliary tips are connected together with proteinaceous link that opens 
mechanically gated ion channels when the stereocilia move. The flow of ions through the 
channel induces neuronal impulse. In noisy environment stereocilia bend and channels are 
open. In order to percept further changes in sound, ion channels need to be closed first and 
then re-open by promoted bending of stereocilia. This is called adaptation. Myosin 1c was 
shown to have direct function in this process since upon its inhibition the adaptation is 
slow and inefficient (Stauffer et al., 2005) (Figure V). Interestingly, a clinical study 
focused on identification of mutation in this protein revealed 6 missense mutations in 







Figure V. Schematic overview of the adaptation process (Gillespie and Muller, 2009) 
18 
 
Several research groups studied function of myosin 1c in adipocytes. Initially, the group of 
Michael Czech provided evidence that Myo1c facilitates the transport of glucose across the 
plasma membrane. Stimulation of adipocytes with insulin leads to translocation of the 
glucose transporter GLUT4 from perinuclear region toward the plasma membrane.  
Myosin 1c was shown to be necessary for incorporation of the transporter into the plasma 
membrane (Bose et al., 2002; Bose et al., 2004). It was shown later that insulin-stimulated 
glucose transport requires the activation of small G protein RalA (Figure VI) and its 








Figure VI. Glut4 incorporation into plasma membrane requires Myo1c (Chen et al., 
2007) 
Expression of myosin 1c was also detected in different cell types of kidney (Wagner and 
Molitoris, 1997). In epithelial cells lining up the surface of kidney collecting ducts,  
myosin 1c was shown to regulate sodium transport. Similarly to function of glut GLUT4 
transport, the role of Myo1c could be the regulation of epithelial sodium channel insertion 
into plasma membrane (Wagner et al., 2005). In addition to collecting ducts, Myo1c 
expression in podocytes appears to be necessary for the formation of cell-cell junctions and 
tightening of the glomerular filtration barrier (Arif et al., 2011). 
The above mentioned functions myosin 1c are extended by regulation of cortical actin 
dynamics in Xenopus oocytes (Sokac et al., 2006), maintaining tension in neuronal growth 
cones (Diefenbach et al., 2002; Wang et al., 2003), phagocytosis in macrophages (Allen 
and Aderem, 1995) and formation of the immunological synapse in B type lymphocytes 
(Maravillas-Montero and Santos-Argumedo, 2011).  
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Taken together, the shorter isoform of the two myosins - myosin 1c - appears to be 
involved mainly in exocytosis and maintenance of the cytoskeleton-plasma membrane 
adhesion. 
3.9. NM1 protein 
NM1 protein shares the same sequence as Myo1c with one exception, which is the 
presence of additional 16 amino acids at the N-teminus of NM1. It is known to bind actin, 
ATP and calmodulin (Nowak et al., 1997) while direct binding partner of the positively 
charged tail domain is yet to be identified. Nevertheless, there is some evidence that it 
could bind electrostatically to naked DNA (Hofmann et al., 2006a) or RNA (Obrdlik et al., 
2010). On the other hand, the sequence of Myo1c and NM1 tails are essentially the same, 
therefore one could reasonably expect that NM1 is able to bind PIP2 as well. Interestingly, 
NM1 protein was shown to associate with the principal controller of RNA polymerase I 
transcription, with TIF1A (Philimonenko et al., 2004). However it is not known whether 
the interaction is direct or mediated via some of the NM1 direct binding partners.  
The biochemical characteristics of this protein are yet to be measured, but based on the 
high sequence similarity between Myo1c and NM1 one can assume that NM1 is also a 
non-processive low duty ratio motor, with slow rate of the ATP hydrolysis. 
Mechanistically, one can expect that its basic function is to maintain tensions as proposed 
for Myo1c (Laakso et al., 2008). The exact function of the N-terminal extension in NM1 
molecule that makes the only known difference from Myo1c is uncertain. However, the 
observation that NM1 is localized mainly in the nucleus and Myo1c at the plasma 
membrane has led to the opinion that the N-terminus could function as a nuclear targeting 







Scheme 3. Domain structure of NM1 protein 
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3.9.1. Cellular functions of NM1  
The main difference from Myo1c was that in addition to plasma membrane, NM1 localized 
as the first myosin ever also to the cell nucleus (Nowak et al., 1997). Initial hinting on 
NM1 functions revealed that it is involved in control of DNA transcription. To date, there 
is ample evidence for involvement of NM1 in transcription by RNA polymerase I and II 
(Pol I and Pol II). NM1 co-localized with both polymerases at the sites of transcription 
(Nowak et al., 1997; Fomproix and Percipalle, 2004; Philimonenko et al., 2004; Kysela et 
al., 2005; Philimonenko et al., 2010), and physically associates with both Pol I and Pol II 
complexes (Philimonenko et al., 2004; Hofmann et al., 2006b). In-vivo rate of transcription 
is affected by NM1 overexpression, knock-down and nuclear microinjections of anti-NM1 
antibodies. In an in-vitro transcription system, anti-NM1 antibodies inhibit transcription by 
both polymerases in a dose-dependent manner, whereas adding purified NM1 increases 
transcription (Pestic-Dragovich et al., 2000; Philimonenko et al., 2004). Transcription 
initiation assays have revealed that NM1 exerts its function in early steps of Pol I and II 
transcription, after the formation of pre-initiation complexes (Hofmann et al., 2006b; Ye et 
al., 2008). Indeed, NM1 interacts with Pol I transcription factor TIF-IA, which is present 
only in initiation-competent fraction of Pol I complexes (Grummt, 2003), and actin that is 
associated with RNA polymerase I independently of transcription. According to (Grummt, 
2006), the binding of NM1 to Pol I via actin may help to initiate transcription by recruiting 














This model is further supported by the fact that functional motor domain is needed for 
interaction of NM1 and Pol I (Ye et al., 2008). In addition to transcription initiation, NM1 
is also involved in Pol I transcription elongation since it associates with the chromatin 
remodeling complex WSTF-SNF2h and might therefore recruit this complex to the 
actively transcribing genes  (Percipalle and Farrants, 2006).  
Interestingly, nascent ribosomal particles seem to be accompanied by NM1 during 
transport from nucleolus toward the nuclear pores (Obrdlik et al., 2010). Furthermore, 
blocking of NM1 or actin by antibodies results in nuclear retention of small ribosomal 
subunits (Cisterna et al., 2006; Cisterna et al., 2009).  
A role of acto-myosin motor in repositioning of chromosomes is also emerging (Hu et al., 
2008; Mehta et al., 2010). In pioneering work, (Chuang et al., 2006) and co-workers 
showed that labeled artificial gene loci move upon activation toward the center of nucleus 
and that overexpression of mutated NM1 that lacks motor activity inhibits this effect. 
However, the exact mechanism behind these translocation phenomena is not clear.  
Of particular interest is emerging role of NM1 in estrogen signaling. NM1 was shown to be 
involved in chromosomal interaction of estrogen-activated genes (Hu et al., 2008). It was 
also co-purified with estrogen receptor α (Ambrosino et al., 2010). 
3.10. Other myosin motor proteins in the nucleus 
Currently, there are 5 other myosin molecules that were observed in the nucleus (myosin 














They have some interesting properties. Myosin VI that was shown to be associated with 
RNA polymerase II is able to move along actin to the opposite direction compared to other 
myosins (Vreugde et al., 2006). 
Myosin V localizes to the nucleolus and nucleoplasm, associates with RNA pol I (Lindsay 
and McCaffrey, 2009). Interestingly, it is able to dimerize and to move a cargo over long 
distances processively. Initial experiments with myosin XVIb revealed that it co-localizes 
with the proliferating cell nuclear antigen (PCNA) and its overexpression slows down S-
phase of cell cycle (Cameron et al., 2007). Sequence analysis of this protein predicts low 




















The key motivation behind this dissertation was the fact that nuclear myosin I function has 
been studied only in cultured cells. However, nothing was known about the tissue 
expression and distribution of this myosin. Since it differs from the cytoplasmic myo1c 
only by 16 AA at the N-terminus another interesting question was: What is the function of 
this N-terminal extension? Naturally, one could predict that these 16 AA are bringing NM1 
into the nucleus. However, solid data supporting this hypothesis were missing.  And least 
but not last, despite the evidence that NM1 is involved in control of transcription the exact 
mechanism how it fulfills this functions is unknown. To understand it in detail, we decided 
to identify the proteins that associate with NM1 (either directly or indirectly). During the 




What is the expression and localization pattern of NM1 in mouse tissues?  
Which NM1 domain is responsible for the nuclear localization of the protein? 













6.1. Experimental part I - Expression and localization pattern of NM1 
in mouse tissues 
To extend the amount of information available about nuclear myosin, we investigated the 
tissue expression pattern, the tissue localization pattern of this protein as well as the 
regulation of NM1 expression. High degree of evolutionary conservation usually points to 
some important function; therefore we searched for NM1 othologues in different species. 
6.1.1. NM1 is ubiquitously expressed and its amount in tissues varies 
Different levels of NM1 expression in tissues could suggest certain tissue-specific 
functions. We have therefore screened eleven mouse organs: small intestine, pancreas, 
brain, kidney, skin, heart muscle, testis, striated muscle, spleen, liver, and lungs by 
immunofluorescence microscopy (Fig. 1). We observed nuclear staining in all cell types 
examined but no obvious differences in signal intensity were observed in nuclei of various 
cell types. There was only one exception - cells in the latest stages of spermatogenesis, 
which were completely negative.  
We also examined the expression of NM1 in these tissues by Western blot (Fig. 2b). 
Intriguingly, the amount of NM1 in lungs was many times higher than in any other tissue. 
Relatively high levels of NM1 were also found in the small intestine, kidney, skin, heart, 
testis, spleen, and liver. Low levels were detected in pancreas, brain, and skeletal muscle.  
Next, we compared the tissue levels of NM1 and cytoplasmic Myo1c. Since Myo1c differs 
from NM1 only by missing 16 amino-acid epitope, there is no antibody available that 
would recognize Myo1c specifically. We used therefore an antibody directed against the 
tail of Myo1c recognizing both Myo1c and NM1. The tissue levels in this case were 
similar to NM1, however, the signal in lungs is not so prominent and there is relatively 
stronger signal in intestine, pancreas, kidney, heart, and liver. We were also able to 
separate the two myosin isoforms in 3T3 cells and liver tissue by SDS-PAGE. Two distinct 
bands were distinguished when stained by the antibody recognizing Myo1c tail while the 
anti-NM1 antibody recognized only the upper band. In both 3T3 cells and mouse liver 
sample (same as in Fig. 2b) the NM1 band was about two to three times weaker than 




















































Fig. 1 NM1 is present in nuclei of all mouse tissues. Confocal immunofluorescence microscopy 
on cryosections shows that NM1 is present in nuclei of all tissues tested with one exception—there 






To quantify the NM1 mRNA, we performed real-time RT-qPCR in the same tissues as 
above. The primers were designed to anneal to 5′ region unique to NM1 and therefore they 
detected NM1 mRNA specifically. The amounts of NM1 mRNA are shown relatively  
to total RNA in samples. We found the highest levels of NM1 mRNA in lungs, medium in 















Fig. 2 Expression of NM1 varies in mouse tissues. a) Total RNA was isolated from mouse 
tissues and identical amounts were analyzed by quantitative RT-PCR. Measurements were 
repeated with samples from five to eight animals except for skin where only one sample was of 
sufficient quality, and lungs where samples from two animals were taken only after finding of the 
high expression on the blot. Averages and standard errors are shown. b) Western blot of NM1 and 
Myo1c in the same tissues. A total of 65 μg of proteins were loaded, β-actin serves as loading 
control  
6.1.2. The expression of NM1 is stimulated by serum 
To test the connection of NM1 expression with cell proliferation, we measured the 
response of NIH 3T3 cells to serum. The cells were first starved in 0.1% serum medium for 
48 h and then stimulated by addition of medium containing 10% serum. The amount of 
mRNA for NM1 was then measured by RT-qPCR (Fig. 3a). Results were normalized to 
total RNA. The levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β-
actin mRNAs are shown for comparison. Actin mRNA was found previously in a similar 
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experiment not to change relatively to total mRNA levels (Iyer et al., 1999) so it can 
represent an “average” transcript. The amount of mRNA for NM1 as well as for actin and 
GAPDH halved during serum starvation but increased during 2–4 h after serum 
stimulation, and then slightly decreased. NM1 mRNA was activated by serum more than 
the housekeeping genes’ mRNA. Additional RT-qPCR experiments showed that NM1 
expression rose gradually during the first two hours of serum activation (data not shown). 
However, on the protein level, the amounts of NM1 relatively to total protein content did 
















Fig. 3 Transcription of NM1 raises during serum activation. NIH 3T3 cells growing in medium 
with 10% serum were subjected to 0.1% serum for 48 h and then returned to 10% serum medium. 
a RT-qPCR quantification of mRNA for NM1, actin, and GAPDH. Samples were run in duplicates, 
and standard deviations are indicated. b Western blot analysis of NM1 expression. Identical 
amounts of protein were loaded; tubulin serves as a loading control  
6.1.3. The lifespan of NM1 is longer than 16 h 
To assess the stability of NM1, we treated NIH 3T3 cells with protein synthesis inhibitor 
cycloheximide at concentration 2 μg/ml for 16 h and observed the levels of NM1. This 
concentration of cycloheximide was chosen because half of this concentration was reported 
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to completely block translation in Chinese Hamster Lung cells (Yildirim and Whish, 1997) 
and it did not cause morphological signs of apoptosis. The levels of NM1 did not change 
significantly during 16 h while the amount of control tubulin already started to decrease 











Fig. 4 NM1 is not significantly degraded during 16 h of translation block. Western blot 
analysis of 3T3 cells treated by 2 μg/ml cycloheximide and harvested in indicated time points  
6.1.4. The specific N-terminal sequence of NM1 is identical in mammals and 
conserved in vertebrates 
Information on NM1 phylogenetic conservation could suggest how fundamental is the role 
of NM1 in transcription. To test this, we examined the expression of NM1 in 
representatives of various animal classes, namely in human, mouse, chicken, Xenopus 
laevis, zebrafish, and C. elegans. Using immunoblot, we found a signal with the mobility 
corresponding to NM1 in human (HeLa) and mouse (NIH-3T3) cell lines, mouse liver, 
chicken lungs, but not in chicken liver, Xenopus lungs, zebrafish, and C. elegans (Fig. 5). 
In the Xenopus liver, we found a band with slightly higher mobility than other samples. In 
chicken, these results can be explained by weak binding of the antibody to varied epitope, 
which is compensated by a high expression of NM1 in lungs. In Xenopus there is no signal 
in lungs and slightly smaller protein is detected in the liver, therefore we cannot exclude 
that the antibody does not recognize Xenopus NM1, but cross-reacts with another protein 
in the liver extract.  
In the next step, we analyzed the NM1 sequences in the genomic databases of various 
species. In every model animal, we selected one or two genes homologous to mouse 
Myo1c by similarity search and then searched in approximately 10–15 kb upstream region 
of the genomic sequence for an intron coding for a sequence similar to the NM1 N-
terminus. Expression of a sequence identical to mouse NM1 N-terminus was predicted by 
gene prediction software in the genome of human, dog, cow, and rat. Furthermore, similar 
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NM1 N-terminal sequences were found in a genome of chicken (50% identity), Xenopus 
tropicalis (60% identity), and zebrafish (41% identity). We have also found N-terminal 
sequences 35% identical to mammalian ones in the genome of pufferfish (Fugu rubipes) 
and Tetraodon nigroviridis. In contrast, genomic analysis identified no sequences similar 
to NM1 N-terminus in urochordate Ciona intestinalis, Drosophila, or C. elegans (Fig. 6; 
for a complete phylogenetic tree, see Fig. 7). To test whether these N-terminal sequences 
are really expressed in the predicted form, we performed a 5′ RLM-RACE analysis in 
selected species. The results are summarized in the Table 1. We confirmed that a sequence 
corresponding to NM1 16 amino-acid N-terminus is expressed in human, mouse, chicken, 
and zebrafish. We have not detected the expression in Xenopus laevis, but an expression of 











Fig. 5 NM1 in various species as detected by western blot. Total protein (50 μg) extracted from 
indicated tissues of different organisms were separated by western blot and tested by polyclonal 














Fig. 6 NM1 is conserved in mammals and expressed in vertebrates. Alignment of NM1 N-
terminal sequences from organisms where it was found to be expressed. Residues with black 
background denote identity with consensus, gray background marks conservative substitution. The 









































Fig. 7 An unrooted phylogenetic tree of putative Myo1c homologs. Sequences similar to 
Myo1c were found by BLAST in protein, nucleotide, and genomic databases. Sequences from 
different organisms most similar to Myo1c were selected and some members of other mammalian 
myosin I subclasses were added for comparison. Alignment was made by ClustalW, and the tree 
was constructed and bootstrap tested by minimum evolution algorithm. This tree served to choose 
candidates for further search for the sequences similar to the NM1 N-terminal. The genes in green 
were shown to express a sequence similar to N-terminal sequence by RACE, and in red the genes 
with an exon coding for a similar sequence as found by analysis of genomic sequence. In Rana 
catesbeiana, we did not perform RACE and the genome is not sequenced, therefore we were not 
able to find the N-terminus. In fish, there are two distinct homologs of Myo1c that probably arose by 
genome duplication in teleost fish lineage (Jaillon et al., 2004). Only one of these, however, 
contains the NM1 N-terminal sequence. We have found the N-terminus neither in Ciona intestinalis 
nor in other more distant organisms genomic sequence. Scale bar shows evolutionary distance in 





Table 1 Results of 5′ RACE of myosin IC genes  
Species NM1 Myo1c 
Mouse EB724369 EB724364-8
Human EB724371-3 – 
Xenopus laevis – EB724387 
Chicken EB724384, EB724386 EB724385 
Danio rerio  EB724379 EB724375-8
GenBank accession numbers are stated where the RACE matched with database sequences of NM1 and 
Myo1c 
 
6.2. Experimental part II – Identification of the nuclear localization 
signal of NM1 
Nuclear myosin I (NM1) was the first molecular motor identified in the cell nucleus. 
Together with nuclear actin, they participate in crucial nuclear events such as transcription, 
chromatin movements, and chromatin remodeling. NM1 is an isoform of myosin 1c 
(Myo1c) that was identified earlier and is known to act in the cytoplasm. NM1 differs from 
the "cytoplasmic" myosin 1c only by additional 16 amino acids at the N-terminus of the 
molecule. This amino acid stretch was therefore suggested to direct NM1 into the nucleus. 
We focused here on identification of mechanism that is responsible for nuclear 
translocation of NM1. 
6.2.1. NM1 is transported to the nucleus after mitosis 
To study the dynamics of NM1 compartmentalization during cell cycle we followed the 
localization pattern of the endogenous NM1 during and after mitosis. Immunofluorescent 
labeling of NM1 in unsynchronized U2OS (Fig.8A) and in NIH 3T3 (Fig.8B) cells 
synchronized by mitotic shake off has shown that NM1 did not stay bound to chromatin 
during the mitosis and that its majority was released into the cytoplasm after the nuclear 
envelope breakdown in prophase (Fig. 8B). Soon after the reconstitution of nuclear 
envelope in early G1, most of NM1 was in the cytoplasm as shown in Fig. 8A and 8B 
(Early G1). In unsynchronized population of cells, this pattern was very rarely observed, 
and the vast majority of cells had clearly nuclear staining of NM1 (Fig. 8A, Interphase). 



















Figure 8: Localization NM1 during mitosis 
(A) Unsynchronized U2OS cells were fixed and labeled with antibody to NM1. Localization of NM1 
is shown at various stages of mitosis. DNA was visualized by DAPI.  (B) Mitotic NIH 3T3 cell were 
seeded onto the poly-L-lysine coated coverslips, fixed and labeled with antibodies to NM1 and 
Lamin B1. Cells fixed immediately after seeding (Prophase) and 15 min after seeding (Early G1, 15 
min post shake-off). Nuclear lamina was reconstituted in Early G1 as visualized by Lamin B1 
labeling. All immunofluorescence pictures were obtained using confocal microscope, single 
confocal sections are shown. Scale bar: 10 µm. U2OS cells were transiently transfected with NM1-
V5/His. 24 hours after transfection cells were treated with nocodazole (C) or aphidicolin (D), to stall 
the cells either in G2/M or in G1/S phase of cell cycle. After the release from the block cells were 
cultivated for another 24 hours. Samples were taken in indicated time points. Cells were labeled 
with antibody to V5 tag, patterns counted and divided into three groups according to the localization 
of fluorescent proteins. More than 100 cells were counted in each time point, experiment was 






To begin identifying import signals in NM1, we first tested the localization of full length 
NM1 constructs fused to different tags. Untagged overexpressed mouse and human NM1 
localized predominantly in the nucleus in 80% of cells, and V5/His-tagged NM1 was 
predominantly nuclear in 50%, whereas EGFP-tagged or FLAG-tagged NM1 was 
predominantly nuclear in less than 20% of cells (data not shown). Further studies used the 
V5/His-tag because it interfered with nuclear import the least.  
To visualize the timing of V5/His-tagged NM1 (NM1-V5/His) transport into the nucleus 
after mitosis, we transfected U2OS cells and the next day added either nocodazole 
(depolymerizes microtubules) or aphidicolin (DNA polymerase inhibitor) for 16 hours to 
accumulate cells in M-phase or S-phase respectively, then washed out the inhibitor and 
used indirect immunofluorescence to localize NM1-V5/His at different times after release 
from the block (Fig. 8C,D). Nocodazole-treated (metaphase-enriched) cells continued with 
mitosis after washout. The lowest nuclear levels of tagged NM1 were seen at 2 and 4 hours 
after release, but increased gradually at 6-10 hours after release (Fig. 8C). After release 
from aphidicolin, cells maintained high nuclear levels of NM1-V5/His for ~11 hours, 
consistent with the expected time needed to complete S-phase and enter G2 (Fig. 8D). The 
lowest levels of nuclear NM1-V5/His were detected 17 hours after release from aphidicolin 
(Fig.8D), when many cells were in mitosis or early G1. Together these results suggested 
both endogenous and tagged NM1 are released from the nucleus during mitosis. 
Endogenous NM1 is transported into renewed nuclei shortly after the nuclear envelope 
reconstitution in the early G1, while nuclear import of the ectopically expressed NM1 with 
a tag is slower.   
6.2.2. First two IQ domains are needed for nuclear transport of NM1 
Because the N-terminal part of NM1 was suggested to be crucial for nuclear localization 
(Pestic-Dragovich et al., 2000), we prepared various deletion and truncation mutants of the 
NM1 in fusion with V5/His at its C-terminus. We compared their localization in U2OS 
cells with the full length NM1-V5 which was detected in the cytoplasm and faintly the 
nucleus (Fig. 9A, anti-V5). Surprisingly, the deletion of the neck and the tail domain led to 
the cytoplasmic retention of the mutant (Fig. 9B). This suggested that the NLS sequence is 
located within the neck or in the tail domains. After deletion of the head domain, we 
observed enhanced nuclear signal with short C-terminal V5/His (not shown) as well as 
with the bulky N-terminal EGFP tag (Fig. 9C).  This suggested that the EGFP-fused 
myosin neck-tail fragment is imported efficiently. Further deletion of half of the tail 
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disrupted the plasma membrane association of the protein but not its nuclear translocation 
(Fig. 9D). The tail together with the third IQ domain of the neck stayed out of the nucleus 
and associated with plasma membrane (Fig. 9E) while the construct with first two IQ 
domains was located exclusively to the nucleus and nucleoli (Fig. 9F). This localized a 
putative nuclear localizing sequence within the first two IQ domains of NM1 neck residues 
712-770. 
6.2.3. The second IQ domain contains a novel NLS sequence 
To pinpoint the exact part of the neck needed for nuclear translocation, we prepared a set 
of fusion constructs containing GFP and the cytosolic pyruvate kinase (PK) enzyme 
(Frangioni and Neel, 1993). We used PK to enlarge the proteins so that they would not 
diffuse passively to the nucleus as GFP alone would (Mohr et al., 2009). The 87 kDa GFP-
PK fusion construct was located solely to the cytoplasm (Fig. 9G). When the sequence of 
the first two IQ domains was added to GFP-PK strong nuclear and nucleolar signal was 
observed (Fig. 9H). Next, we examined the capability of each IQ domain to drive the 
nuclear transport (Fig. 2I, J). Nuclear accumulation was specifically driven by the second 
IQ motif (Fig. 9J), not the first IQ motif (Fig. 9I). The IQ2 motif and its C-terminal 
flanking sequence contain two clusters of basic amino acids. Next, we preserved only the 
basic amino acid clusters with the intermitting non-polar amino acids, resulting in 13 
amino acid peptide, 754GRRKAAKRKWAAQ766. This sequence was sufficient for nuclear 
translocation (Fig. 9K). On the other hand, the N-terminal 16 amino acids from NM1, 
fused to the N-terminus of the GFP-PK construct, did not localize to the nucleus at all (Fig. 
9L). To rule out the possibility that it serves as a nuclear retention signal, we fused the N-
terminal sequence to EGFP that diffuses freely into nucleus. We did not observe nuclear 
enrichment of the signal that would be caused by an interaction of the protein inside the 
nucleus (not shown). In contrast to the full length NM1 (Fig. 10A), a C-terminally fused 
NM1 construct lacking the residues 739-762 accumulated in the cytoplasm of U2OS cells 
(Fig. 10B), supporting an important role for the second IQ. No single K/R-to-A 
substitution in residues 754-766 was able to disrupt the NLS activity (data not shown). 
However mutating all 6 basic residues to alanines completely abolished nuclear import 
(Fig. 10C; NM1-V5-mutNLS). NLS Database (Cokol et al., 2000) and literature searches 
revealed no known NLS homologous to that of NM1. We therefore concluded that NM1 
























Figure 9: Neck domain of NM1 contains the NLS  
U2OS cell transfected with a panel of truncation constructs of full length NM1 (A-F) and IQ 
domains fused to GFP-PK (G-L). Cells were fixed 48 hours post transfection. Below the pictures 
are schematic representations of the truncations affecting various NM1 domains as well as the 
GFP-PK phusions. Pictures (A-F) were acquired using confocal microscope, single confocal planes 




6.2.4. Myo1c is able to translocate into the nucleus 
N-terminus of NM1 alone did not possess a nuclear localization potential and the NLS was 
located in region shared by both the NM1 and Myo1c. We therefore inspected the 
















Figure 10: Mutation of basic residues in the neck of NM1/Myo1c abolishes its nuclear import 
U2OS cells were transfected with with full length NM1-V5/His (A), NM1-V5/His lacking the second 
IQ motif (B), and NM1-V5/His with point mutation of basic amino acids within the NLS into alanines 
(C). Below the pictures are schematic representations of constructs used. Color coding is the same 
as in Fig. 2. Cells were fixed 48 hours post transfection and labeled with anti-V5 antibody, pictures 
were obtained using wide-field microscope, scale bar: 10μm (D) U2OS cells  transiently transfected 
with Myo1c-V5/His show nuclear localization of the protein Picture is a single confocal plane, 
obtained by confocal microscope. Scale bar: 10μm. (E) Nuclear and cytosolic extracts were 
prepared from liver of either wild type (WT) or NM1 knock-out (KO) mice. Equal amount of protein 
was resolved using SDS-PAGE and electro-transferred to nitrocellulose. Membrane was probed 
with anti-NM1, anti-Myo1c, anti hnRNP C1/C2 and GAPDH antibody. Signal was detected using LI-
COR Odyssey infrared imaging system. (F) U2OS cells were transiently transfected with Myo1c-
V5/His. 24 hours after transfection cells were treated with nocodazole or aphidicolin to stall the 
cells either in G2/M or in G1/S phase of cell cycle. After the release from the block cells were 
cultivated for another 24 hours. Samples were taken in indicated timepoints. Cells were labeled 
with antibody to V5 tag, patterns counted and divided into three groups according to the localization 
of fluorescent proteins. More than 100 cells were counted in each timepoint, expreriment was 
repeated twice with similar result. 
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V5/His tagged Myo1c was localized to the nuclei of transfected U2OS cells (Fig. 10D). 
The nuclear localization of Myo1c-V5/His in nocodazole- or aphidicolin-treated cells was 
also cell cycle dependent, with profiles (Fig. 10F) similar to that of cells that 




















Figure 11: Co-localization of overexpressed NM1 and Myo1c 
U2OS cells were co-transfected with FLAG-tagged NM1 (NM1-FL) and V5/His tagged Myo1c 
(Myo1c-V5/His). Cell showing nuclear localization of NM1 and Myo1c was photographed using 
confocal microscope (A). U2OS were transfected with Myo1c-V5/His. 48h post transfection cells 
were fixed, and labeled with polyclonal antibody (R2652) directed toward the tail region of 
NM1/Myo1c and with monoclonal antibody against V5 (B). Intensity profiles along the regions of 
interest in the nucleus and nucleolus are shown under the pictures. White arrows are pointing to 





To test the influence of the N-terminal 16 amino acids on NM1 functions we prepared 
knock-out mice lacking the exon-1 that contains the NM1 translation start codon (Venit et 
al, in preparation). Resulting mRNA contains only the downstream start of translation 
which gives rise to Myo1c protein. We used purified liver nuclei from NM1 knock-out 
mice to confirm that the N-terminus is not required for nuclear transport of endogenous 
NM1. Fig. 10E shows the presence of Myo1c in the purified liver nuclei from NM1 knock-
out mice visualized by antibody to the C-terminus of NM1/Myo1c. Weak signal of 
GAPDH indicates negligible contamination of nuclei with cytosol, while signal of hnRNP 
C1/C2 shows marked enrichment of nuclear proteins compared to cytosolic liver extract. 
This shows that both NM1 and Myo1c have the ability to enter the nucleus. Further, we 
have observed the co-localization of NM1 and Myo1c in a single cell. However, we were 
not able to co-localize NM1 and myo1c in nuclei of untransfected cells using the 
polyclonal antibody directed to the tail region of NM1/Myo1c (R2652) (Dumont et al., 
2002) since it failed to label endogenous epitopes within nuclear environment.  Therefore, 
U2OS cells were cotransfected with FLAG tagged NM1 and V5/His tagged Myo1c. Fig. 
11A shows a cell expressing both proteins. Myo1c and NM1 co-localized at the plasma 
membrane (arrows) and in the nucleus. Interestingly, R2652 antibody revealed the signal in 
nucleus and nucleolus when Myo1c was overexpressed Fig. 11B.  
6.2.5. Importins bind the NM1 neck region 
The transport of nuclear proteins through nuclear pores is often facilitated by importins 
that recognize their NLS in cytoplasm (Cokol et al., 2000). To discriminate between 
cytoplasmic and nucleus/plasma membrane-associated myosin, cells were extracted with 
buffers containing digitonin that is known to extract cytosolic myosin 1c (Chen and 
Wagner, 2001). We sought to identify the transport receptors that bind NM1/Myo1c NLS. 
Using pull down assay with recombinant IQ12 as the bait we identified importin 5 (IPO5) 
and Heat shock protein 90 beta (HSP90) as the proteins that associate with IQ12 in the 
cytoplasm of HeLa cells (Fig. 12A). To verify the obtained result by another method, we 
looked for interacting partners of GFP-NM1-(Q123.T) in HEK-293T cells. Mass 
spectrometry analysis of bands that co-purify specifically with GFP-NM1-(Q123.T)  
but not with the control Str-GFP contruct, revealed importin 5, importin 7 (IPO7), 
importin-β1 (KPNB1) and HSP90 beta (Fig. 12B). Additional bands that were present on 
the gel were not identified. To verify that the importin 5, importin 7 and importin-β1, 
which were found to bind the truncated constructs, recognize also the endogenous protein, 
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we performed co-immunoprecipitation with a polyclonal antibody directed to N-terminus 
of NM1. Since most of endogenous NM1 molecules potentially accessible to importins are 
located in cytosol of the G1 cells (Fig 8A), we synchronized the HeLa cells with 
nocodazole and harvested them 3 hours after nocodazole wash-out. As shown by western 
blot (Fig. 12C), endogenous NM1 specifically binds to importin 5 (IPO5), importin 7 
(IPO7), and importin-β1 (KPNB1) in digitonin extracts of the G1 cells. Next, to confirm 
that importin 5 binds specifically to NM1 NLS via the interaction with positively charged 
amino acids, we compared the proteins that co-purify with headless NM1 with wild type 
NLS (GFP-NM1-(Q123.T) NLSwt) and headless NM1 with all basic residues in the NLS 
mutated to alanines (GFP-NM1-(Q123.T) NLSmut) from electroporated HEK293T cells. Fig. 
12D shows that importin 5 interacts only with GFP-NM1-(Q123.T) NLSwt and that this 
interaction occurs in digitonin extract in contrast to triton X-100 that liberates the plasma 
membrane bound myosin (Chen and Wagner, 2001). Taken together, the aforementioned 
data show that the importin 5, importin 7 and importin-β1 bind the newly identified NLS.  
6.2.6. NM1 nuclear import does not follow the canonical nuclear import pathway 
The small GTPase Ran controls the direction of canonical nuclear import pathway. High 
levels of GTP-loaded Ran in the nucleoplasm cause the dissociation of importin-cargo 
complex upon translocation through the nuclear pore complex (Pemberton and Paschal, 
2005). We probed the stability of the NM1-importin complexes in the presence of RanGTP 
in order to test whether the nuclear import of NM1 follows the canonical nuclear import 
pathway.  
Complexes containing Str-GFP-NM1-(Q123.T) and associated importins were purified 
from electroporated HEK293T cells using streptactin affinity column and incubated with 
recombinant Q69L mutant of Ran, preloaded with GTP. This mutant is not able to 
hydrolyze GTP (Kutay et al., 1997) and should cause elution of importins from the Str-
GFP-NM1-(Q123.T) column  The activity of Q69L mutant of Ran was confirmed by its 
ability to dissociate importin β1 from its well known cargo, SV40 NLS (Fig. 12E). In 
contrast to SV40 NLS, the GFP-NM1-(Q123.T) remained associated with importin 5 even 
in the presence of RanGTP Q69L. As shown by western blot (Fig. 12E), the complex of 
GFP-NM1-(Q123.T) and importin 5 co-eluted from the column by the addition of biotin 
















Figure 12: Identification of NM1 interacting proteins in the cytosol 
Digitonin extract from suspension HeLa cells was incubated with recombinant Str-IQ12-His peptide 
containing N-terminal OneStrep tag (IQ12) and Streptactin beads as a control for background 
binding. Bound proteins were resolved on 4-20% SDS-PAGE gel and stained with SimplyBlue. 
Mass spectrometric analysis of the protein bands that co-purified with bait (arrows) identified 
importin 5 and heat shock protein 90 beta (HSP90) (A). SimplyBlue stained 4-20% SDS-PAGE gel 
with proteins that interacted with Str-GFP-NM1-(Q123.T) and Str-GFP as a control in digitonin 
extract of HEK293T cells. The arrows show positions of bands  that contained proteins identified 
using mass spectrometry as importin 5, importin 7, importin-β1, HSP90 beta and calmodulin (B). 
Proteins that co-immunoprecipitate with antibody to endogenous NM1 from HeLa extracts were 
resolved using SDS-PAGE and tranferred onto nitrocelulose membrane. Membrane was probed 
with with anti-NM1, anti-importin 5 (IPO5), anti-importin 7 (IPO7), anti-importin-β1 (KPNB1). Rabbit 
polyclonal antibody against GFP was used as a control for backgroung binding (C). N-terminally 
Strep tagged GFP-NM1-(Q123.T) NLSwt (wt), GFP-NM1-(Q123.T) NLSmut (mut) and GFP as negative 
control (nc) were expressed in HEK293T cells. Cells were extracted with buffer containing digitonin 
(digi) to obtain soluble cytosol; pellet was re-extracted with the same buffer containing 1% Triton X-
100 (triton). Bound proteins were resolved on SDS-PAGE, transferred to nitrocelulose. Membrane 
was incubated with antibody to importin 5 ans GFP (D). Beads containing Str-GFP-NM1-(Q123.T) 
and Str-GFP-SV40 NLS and associated proteins were eluted first with buffer containing GTP-
loaded RanQ69L or buffer alone and then with biotin containig buffer that liberated Strep-tagged 
bait proteins from the column. Proteins eluted from the beads were resolved on SDS-PAGE and 
transferred to nitrocelulose membrane. GFP, importin 5 and importin-β1 signals were detected 
using specific antibodies (E). Signal from secondary antibodies was detected using LI-COR 
Odyssey infrared imaging system. 
Taken together, these data suggested that the NM1 nuclear import does not follow the 
canonical nuclear import pathway regulated by GTPase Ran. 
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6.2.7. Overexpression of calmodulin negatively influences NM1 nuclear import 
Neck region of NM1 is characterized by the presence of IQ motifs that bind calmodulin in 
Ca2+-dependent manner (Gillespie and Cyr, 2002). As NLS sequence of NM1 is present 
within one of these IQ motifs (Fig13E), we tested the influence of increased calmodulin 
levels on the NM1 localization. When GFP-PK-IQ12 was co-expressed with calmodulin in 
U2OS cells, elevated levels of calmodulin blocked the nuclear import of the IQ12 construct 
















Figure 13: Overexpression of calmodulin influences the nuclear import of NM1 
U2OS cells were co-transfected with GFP-PK constructs containing IQ domains, and calmodulin. 
Calmodulin was visualized using specific antibody (A,B,C). Scale bar 10μm. HEK293T cells 
electroporated with the same constructs as in (A,B,C). Whole cell extracts were subjected to 
immunoprecipitation with anti-GFP nanobody. Bound proteins were resolved on SDS-PAGE and 
transferred to nitrocelulose. GFP and CaM were visualized using specific antibodies (D). (E) 
Comparison of IQ1 and IQ2 sequences. The consensus IQ motif is shown below. The NM1 NLS 
sequence is highlighted in red. 
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Calmodulin, on the other hand, did not block the import of GFP-PK-IQ2 (Fig. 13C). 
Importantly, calmodulin did not inhibit the nuclear import of the GFP-PK-SV40 NLS 
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construct, suggesting that the observed effect is not a general inhibition of nuclear import 
pathways (Fig. 13A). To compare the amount of calmodulin associated with GFP-PK-IQ2 
and GFP-PK-IQ12 we immunoprecipitated the proteins from extracts of electroporated 
HEK293T cells using anti GFP antibody coupled to magnetic beads. As shown in Fig. 
13D, calmodulin associated with GFP-PK construct only when both IQ domains were 
present (GFP-PK-IQ12).  In conclusion calmodulin binding to IQ12 appears to regulate 
nuclear import of NM1. 
6.3. Experimental part III - Identification of novel NM1 interacting 
proteins 
Nuclear myosin 1 (NM1) is an isoform of myosin 1c (Myo1c), both are monomeric and 
belong to the class I of unconventional myosins. NM1 and Myo1c display very high degree 
of sequence similarity, with the only difference; the presence N-terminal peptide at the 
amino terminus of NM1. Although the molecular structure of the two proteins seems to be 
very alike, the functions attributed to them differ. Myo1c was shown to work as a dynamic 
linker between plasma membrane and actin filaments which is a prerequisite for 
mechanotransduction  (Gillespie, 2004), maintenance of actin rich structures such as 
stereocilia and microvilli (Nambiar et al., 2010), and dynamic plasma membrane events 
such as exocytosis (Bose et al., 2004; Sokac et al., 2006). On the other hand NM1, was 
found to play a role in various processes that occur in the cell nucleus. Perhaps the most 
studied one was the role of NM1 in DNA transcription (Fomproix and Percipalle, 2004; 
Philimonenko et al., 2004; Hofmann et al., 2006b). Besides its direct binding protein 
partners, such as actin and calmodulin, NM1 was found to associate with TIF1A, the 
principal regulator of Pol I transcription (Philimonenko et al., 2004), and with the nuclear 
import proteins (Dzijak et al., PlosOne, Accepted). Since the binding to different set of 
proteins could influence the localization, as the next step we identified proteins that 
associate with NM1 in whole cell extracts. We focused on actin and lipid mediated 
interactions of NM1. 
6.3.1. Endogenous NM1 and Myo1c are distributed in the cell equally 
NM1 and Myo1c display very high degree of sequence similarity, with the only difference 
- the presence N-terminal peptide at the amino terminus of NM1. We have shown that the 
N-terminus is not responsible for the nuclear localization of NM1. Furthermore, using 
overexpression we found that the two isoforms do not co-localize entirely (Dzijak et al 
Plos One, Accepted). Therefore we sought to prove that the co-localization pattern 
observed previously with overexpressed proteins applies also to endogenous myosin 
isoforms at steady state. To co-localize endogenous proteins in one cell, we used 
monoclonal antibody generated against the tail domain of myosin 1c that recognizes both 
NM1 and Myo1c (Gillespie et al., 1993). Since we lacked the good quality antibodies to 
NM1, we generated a polyclonal one against the N-terminal peptide (AA 1-16) that was 
affinity purified. The specificity of NM1 antibodies was tested using pre-blocking with the 
N-terminal peptide (Fig.14). Surprisingly, at steady state, the localization of NM1 
















Figure 14. NM1 peptide blocks the signal of NM1 specific antibodies A549 cells were 
incubated with  new anti NM1 antibody (A) and X207 anti NM1 polyclonal (Fomproix and 
Percipalle, 2004) (B) polyclonal antibodies. Specific signal was diminished addition of excess of 
NM1 N-terminal peptide (AA 1-16), (C,D).Pictures were  taken using a wide field microscope. Scale 
bar 10 µm.  
This was in contrast to previous data obtained by other polyclonal antibodies that labeled 
NM1 primarily in the cell nucleus (Pestic-Dragovich et al., 2000; Fomproix and Percipalle, 
2004). Such a discrepancy could be caused either by a posttranslational modification of the 
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NM1 N-terminus that masks the epitope in the nucleus, or by a cross-reactivity of the 
polyclonal antibodies to other nuclear protein. To rule out an influence of posttranslational 
modification occurring within the N-terminus, we compared the immunofluorecent signal 
from previously used antibody (Fomproix and Percipalle, 2004) in mouse skin fibroblasts 
derived from mice lacking the NM1 protein (Fig.15). Strikingly, the only obvious 
difference between NM1-/- and NM1+/+ cells was a severe reduction of the signal in 
cytoplasm of the NM1 knockout cells, while the intensity of the nuclear signal was 
unchanged. We also repeated the experiment using cells expressing shRNA toward the 
NM1/Myo1c. In these cells the level of NM1/Myo1c is reduced by 70% compared to the 
cell expressing control shRNA. The results were identical to those obtained using NM1 
knock out cell line (data not shown). Altogether, these data clearly showed that antibodies 















Figure 15 Localization patterns of NM1 antibodies in NM1 wt and knock out cells. Each 
picture contains a pair of mouse skin fibroblasts derived either from the NM1 WT (Left) or from the   
NM1 KO mouse (Right). A specific signal by the new anti NM1 (R5) (A) and X207 (Fomproix and 
Percipalle, 2004) (B) is present in WT cells.  The X207 contains in addition a unspecific signal in 
the nucleus. (C,D) DNA visualised by DAPI. Pictures were taken using confocal microscope, single 
plane is displayed. Scale bar 10 µm. 
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Therefore, we used the new antibody for co-localization. Similarly to our previous data, 
Fig.16 shows a general high degree of co-localization between NM1 and Myo1c with some 
regions that do not overlap. Because the distribution of NM1 fluorescent signal in cells was 
more cytoplasmic than nuclear, we compared the amount of NM1 in cell compartments 
using biochemical fractionation. In agreement with the immunofluorescence data the 
biochemical fractionation confirmed that at steady state the distribution of NM1 was more 
cytoplasmatic than nuclear (80% cytoplasm/20% nucleus) (Fig.17). Taken together NM1 






Figure 16 Co-localization of NM1 and Myo1c in A549 cells. A549 cells were incubated with the 
NM1specific polyclonal antibody (R5) and a monoclonal antibody that recognized the tail domain of 






Figure 17 Amount of NM1 and myo1c in cytosolic and nuclear fractions. HeLa cells were 
fractionated into nuclear and cytosolic freactions. 60 ug of total protein was loaded in each lline. 
Lamin A was used as a control for cross contamination. NM1 and Myo1c are highly localized in the 
cytoplasm. 
6.3.2. NM1/Myo1c expression is different in tissues and cell lines 
NM1 and Myosin 1c are distributed through the cell similarly. We compared the levels of 
expression of NM1 and Myo1c at the mRNA level previously (Kahle et al., 2007). 
However, because the molecular weight of NM1 and Myo1c are very close to each other, 
we were unable to separate the two isoforms efficiently enough to quantify their amounts 
directly. Therefore, we used Licor Odyssey© fluorescent detection system that enables 
quantification of fluorescent signal in two separate channels. We used a polyclonal 
antibody to the N-terminus and a monoclonal antibody that was generated against the tail 
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domain of NM1/Myo1c. To normalize the signal from the two antibodies, we transfected 
cells with NM1-GFP construct that has the molecular weight 170 kDa. The intensities of 
NM1 and Myo1c were compared in the cytosolic and nuclear extracts of HeLa.  We found 
that in this cell line the ratio between NM1 and Myo1c was 1:1 (Fig.18A) in both cellular 
compartments. To confirm this result, we used the advantage of NM1 knockout cell line in 
which the expression of NM1 is ablated and only Myo1c is expressed. We compared the 
level of total protein NM1+Myo1c using western blot. In KO cell line, we observed 
reduction of signal intensity to about 50% of the wild type cells (Fig.18B). Similar 
reduction in fluorescent signal was observed using immunofluorescent labeling with 
antibody against NM1/Myo1c (data not shown).  We also repeated the quantification using 
NM1 KO lungs and stomach in comparison to WT ones. Here the ratio of NM1 versus 













Figure 18 Quantification of NM1/Myo1c expression (A) HeLa cells were fractionated into 
cytosolic and nuclear fractions. NM1 and Myo1c amounts were quantified using double labeling of 
WB after normalization to NM1-GFP band. (B) Amounts of total NM1 + Myo1c were compared in 
mouse skin fibroblasts derived from NM1 knock-out and NM1 wild type mouse. Graph shows the 
amount of NM1 and Myo1c after densitometric quantification of bands. Beta actin signal was used 
as loading normalizer (C) Amounts of total NM1 + Myo1c were compared in lungs and stomach 
from NM1 knock out and NM1 wild type mouse. Graph shows the amount of NM1 and Myo1c after 





Taken together, in cell types such as the fibroblasts and cancer cell lines the NM1 isoform 
comprises about 50% of total NM1+Myo1c, while the ratio appears to be shifted toward 
the Myo1c isoform in mouse lungs and stomach.  
6.3.3. NM1/Myo1c tissue expression is associated with epithelial and endothelial cells 
To obtain a hint about tissue specific functions of NM1, we measured the level of 
expression of this myosin in various mouse tissues. We identified lungs as the tissue with 
the highest expression of NM1. However, using the commercial antibody available at that 
time, we were not able to identify any differences in NM1 expression within this tissue. 
Therefore, we revisited the tissue localization pattern of NM1 with the antibody that we 
prepared, and carefully validated. In lungs, NM1 is highly expressed in cells that form 
alveoli (Fig.19A). We also re-inspected NM1/Myo1c localization in other tissues such as 
brain, striated muscle and stomach using the polyclonal antibody to NM1/Myo1c (Dumont 
et al., 2002) (Fig. 19B,C,D). In these tissues, the expression was the highest in endothelial 
cells lining up the arteries or forming capillaries (Fig 19C,D). In stomach, secretory 
epithelial cells showed a distinctly high signal, cell-cell contacts of smooth muscle cells 
were also specifically labeled (Fig.19B, and data not shown). Since the highest signal was 
observed in alveolar epithelial cells of lung, we also investigated the localization of NM1 
in the cancer cell line A549, which displays some properties of type II alveolar cells. In 
subconfluent cells, NM1 was highly localized at the dynamic cell edges called 
lammelipodia. In confluent culture of alveolar epithelial cell line A549, NM1 was highly 
enriched at the cell-cell contacts. The endothelium was the second cell type that showed a 
high expression of NM1. We also inspected the localization of NM1/Myo1c in these cells. 
We found a dominant plasma membrane localization pattern with occasional clustering of 






























Figure 19 Localization of NM1/Myo1c in mouse tissues 
Mouse tissues were fixed in PFA, dehydrated in sucrose and frozen. 7-10 µm sections were 
prepared using a cryostat. NM1/Myo1c was visualized using antibody directed to the tail domain of 
NM1/Myo1c. (A) a section thru mouse lungs shows labeling in alveoli and endothelial cells of the 
vein. (B) Transversal section of mouse stomach mucosa shows distinct staining of secretory 
epithelial cells. (C) Longitudinal section of mouse striated muscle shows staining in capillaries that 
intersperse muscular fibers. (D) Labeling of capillaries in a section of mouse cerebral cortex. 
Pictures were obtained using a wide field fluorescent microscope. Scale bar 75 µm. 
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6.3.4. Identification of NM1 associated proteins in whole cell lysates of A549, HeLa, 
H1299 and HUVEC cells 
NM1 binds directly to actin, calmodulin and acidic phopholipids. These are widely spread 
adaptor molecules, present in a variety of different complexes that do not suggest directly 
any specific functions. To obtain a better picture about different cellular processes in which 
NM1 might play a role we sought to identify proteins that associate with NM1 in a cell. 
We also used whole cell extracts in co-immunoprecipitation experiments to capture any 
cytosolic or plasma membrane complexes. Previously, we focused on the identification of 



















Table 2 Proteins that associate with NM1 (A) A549, whole lungs and HeLa cells were lysed 
using indicated buffers. We used Triton to efficiently liberate the lipid associated NM1, and digitonin 
or Tween that do not disturb the binding of NM1 to lipids. Under these conditions we were able to 
follow the actin, or lipid mediated interactions of NM1. We also used Different antibodies to NM1, 
(m) Monoclonal (clone #4, Ye et al), and polyclonal (R5) and M3567 (Sigma-Aldrich). (B) We also 
prepared stable cell lines expressing FLAG-tagged NM1. Cells were lysed in the same buffers as in 
(A). Bands that appeared on the gel specifically in the IP line were cut out and analyzes by MALDI-
FT-ICR instrument. Protein IDs were obtained peptide mass fingerprint using PROFOUND 





This method of lysis, however, does not extract the NM1 that is bound to plasma 
membrane and the nucleus. Therefore, we used also the whole cell extracts prepared by 
various lysis buffers that extract most of cellular NM1 and sought to identify proteins that 
associate with NM1. As starting material for immunoprecipitations we used whole cell 
lysates of the lung cell line A549 that overexpressed FLAG-tagged NM1. We also 
immunoprecipitated endogenous NM1 from A549 cells using various antibodies generated 
toward the N-terminus of endogenous NM1. The conditions of extraction and buffer 
composition were optimized to capture the proteins that could interact with myosin either 
via actin or the lipid-binding domain. We used various detergents such as digitonin (it 
extracts the cytosolic NM1), triton X-100 which extracts the lipid bound myosin, and 
TWEEN-20 (after sonication it solubilized total cellular NM1 but did not disturb the lipid 
binding). Using this approach we identified various actin and PIP2 binding proteins as the 
NM1 associated partners (Table 2).  
 
6.3.5. NM1 associated proteins co-localize with NM1/Myo1c at the leading edge 
Next, we wanted to test where in the cell these proteins co-localize with NM1/Myo1c. We 
used the antibody directed to the tail part of NM1/Myo1c to co-localize the proteins that 
were identified by mass spectrometry in intact A549 cells. Most of the identified protein 
co-localized with NM1/Myo1c at the plasma membrane, more specifically at the leading 

































Figure 20 Co-localization pattern of selected NM1-associated proteins 
A549 cells were fixed and permeabilized with methanol and labeled with antibody to NM1/Myo1c 
together with Myosin 1B (A), Annexin II (B), alpha actinin 4 (C) and Filamin A (D). Pictures were 
photographed using confocal microscope. Scale bar 10 µm. 
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6.3.6. Myo1c is able to functionally substitute NM1 
Since the cellular distribution of NM1 and Myo1c is very similar and the ratio of 
expression is 1:1, we asked the question whether they are functionally identical. The 
siRNA mediated depletion of NM1/Myo1c was shown to decrease of RNA polymerase I 
transcription rate (Philimonenko et al., 2004). We used shRNA against human 
NM1/Myo1c to induce the PolI deficient phenotype and measured the reconstitution of the 
phenotype by overexpression of mouse Myo1c that was resistant to the RNAi. We 
observed the restoration of Pol I transcription rate to almost the endogenous level in RNAi 
depleted cells reconstituted by overepression of either of Myo1c (Fig.21). Taken together 












Figure 21 Restoration of Pol I deficient phenotype 
Human A549 cell line (WT) was transduced with shRNA against human NM1/Myo1c. Total 
NM1+Myo1c RNA was depleted  by 90 % while the protein was depleted by 70% (KD). As a result 
nascent rRNA production was inhibited by 20%. Cells harboring shRNA were transduced with 
construct encoding for the RNAi resistant mouse Myo1c-GFP. The efficiency of transduction was 
about 90%. Myo1c expression was able to bring the nascent rRNA production almost to the level of 













7.1. Discussion Part I - Expression and localization pattern of NM1 in 
mouse tissues 
Since the discovery of NM1 in 1997, several studies showed that it has important functions 
in transcription (for reviews, see (de Lanerolle et al., 2005; Percipalle et al., 2006)). 
However, all data obtained so far have dealt with cell cultures and there is no information 
on tissue-specific expression or phylogenetic distribution of NM1. This paper aims to 
fulfill these gaps and provides also additional data on NM1 concerning the protein lifespan 
and the connection with overall cell metabolism and proliferation. 
The tissue distribution of NM1 is interesting because it might answer the question whether 
NM1 serves a tissue-specific or general role in transcription. These data exist for Myo1c 
and one can compare them conveniently with those on NM1. Wagner et al. (1992) assayed 
the distribution of Myo1c in mouse tissues by western blot finding the highest levels in 
lungs, adrenal gland, and stomach followed by spleen, heart, and esophagus. This study 
was complemented by (Crozet et al., 1997) who compared similar selection of mouse 
tissues by Northern blot and found also the highest levels in lungs followed by kidney, 
spleen, heart, and testis. Similar experiments were performed in rat, and the highest 
expression of Myo1c was observed again in lung, followed by heart and kidney both by 
Northern (Sherr et al., 1993) and Western blot (Ruppert et al., 1995). In the data of Yanai 
(Yanai et al., 2005) who assayed 12 healthy human tissues by Affymetrix GeneChip, the 
expression of Myo1c was again highest in lungs, followed by prostate, heart, and kidney. 
As these studies were not designed to distinguish between Myo1c and NM1, they show 
cumulative levels of both myosin isoforms. In general, our results on the “total” myosin are 
in agreement with these literature data. In addition, we were able to show the expression of 
the nuclear isoform separately. If we take in account that in liver NM1 comprises one-
quarter to one-third of the “total” pool, we can estimate the ratio of both isoforms also in 
other organs. Strikingly, in lung, NM1 seems to comprise the large majority of the “total” 
pool. This suggests some organ-specific functions of the NM1 in lung. 
There is a discrepancy between the observation of similar levels of NM1 in the nuclei of 
different cell types by immunofluorescence microscopy and varied expression detected by 
quantitative PCR and western blot. The tissues differ in the amount of cytoplasmic and 
extracellular protein and thus in the ratio of NM1 to total protein. For example, high 
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amounts of actin and muscle myosin are present in striated muscle while there is much less 
cytoplasmic and extracellular protein in lung tissue this increases the fraction of nuclear 
proteins relative to the total protein. However, the many-fold higher expression of NM1 in 
lungs cannot be explained by this mechanism alone as other nuclear proteins such as Pol II, 
TATA binding protein (TBP), lamin A and C, and nuclear DNA helicase II do not show 
such markedly high expression in lungs (data not shown). In addition, the 
immunofluorescence confocal microscopy has a limited quantitative ability and it is 
therefore not possible to measure differences between various tissues or cell types, unless 
they are dramatic like in the latest stages of spermiogenesis. 
Because NM1 plays a role in transcription it is important to assess how tightly is NM1 
expression regulated in connection with overall transcriptional activity of the cell. We used 
therefore a convenient model of NIH-3T3 cells subjected to serum starvation and 
metabolically reactivated following serum addition. During serum starvation, the cells 
enter G0 phase, and after the addition of serum they reenter the cell cycle while increasing 
overall transcription. The levels of NM1 after serum activation peak after 2–4 h, and the 
transcription of NM1 is increased approximately by 30% when compared to an “average” 
gene like actin or GAPDH. This is a relatively weak response considering that several fold 
change is not uncommon for other highly regulated genes under these conditions (Iyer et 
al. 1999). It is, however, stronger response than that of Pol II or TATA-box binding protein 
(TBP) that respond in a similar fashion as actin (database supplementary to Iyer et al. 
1999). It seems, therefore, that the biochemical activity of NM1 is not regulated chiefly on 
the level of expression but by other mechanisms like calmodulin binding/dissociation (Zhu 
(Zhu et al., 1998), or phosphorylation (Williams and Coluccio, 1995; Gillespie and Cyr, 
2004). 
In order to further characterize the dynamic properties of NM1, the stability of NM1 was 
assessed. Because the treatment with cycloheximide inhibits cytosolic protein synthesis, 
any observed decrease in NM1 presence should reflect mainly NM1 degradation. No 
significant change in cellular NM1 levels was observed following 16 h of cycloheximide 
treatment which indicates that NM1 has a lifespan not shorter than 16 h. In our previous 
study, we have shown that NM1 reaches its minimum level after 48 h after siRNA 
inhibition in HeLa cells (Philimonenko et al., 2004). Taken together, we can estimate the 
lifespan of NM1 molecules between 16 and 48 h. This result is consistent with half-life 
prediction of about 30 h based on the “N-end rule” (Gonda et al., 1989). 
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We found the N-terminal sequence of NM1 to be identical in mammals and the rest of the 
protein is also conserved in mammals with minimum of 95% similarity. The N-terminal 
peptide is also conserved in all vertebrates tested but we have not found it in urochordate 
Ciona intestinalis or any other more distant species. This means that NM1 N-terminal 
sequence appears to be a specific achievement of vertebrate evolution. 
Altogether, NM1 is evolutionary conserved in vertebrates, it has a lifespan between 16 and 
48 h, it is ubiquitously expressed in tissues but with varying intensity, and cellular mRNA 
levels of NM1 are connected with the level of cellular metabolism. These results suggest 
that NM1 is universally needed in vertebrate cells and it could have some tissue specific 
functions especially in lungs. Further studies are needed to elucidate the molecular 
mechanisms underlying these characteristic features of NM1. 
7.2. Discussion part II - Identification of the nuclear localization signal 
of NM1 
Nuclear myosin 1 is ubiquitously expressed protein that localizes to the nuclei of all cell 
types tested so far with the exception of cells in germinal stage of spermiogenesis (Kahle et 
al., 2007). Our previous work described the dynamics of intranuclear relocalization of 
NM1 (Kysela et al., 2005; Philimonenko et al., 2010) and involvement of NM1 in 
important nuclear processes – namely gene transcription. In this paper, we further 
contribute to the knowledge of NM1 cellular trafficking by describing the dynamics of its 
nuclear import and identification of the sequence that is necessary for the nuclear entry of 
NM1.  
7.2.1. NM1 contains NLS within the IQ domain 
We used tagged constructs in search for the NLS of NM1. By deletions and truncations of 
the full length protein, we narrowed down the region of NM1 required for its nuclear 
import to a short sequence within the second IQ motif of the neck domain (Fig.13E). The 
sequence contains clusters of basic amino acids intermingled with non-polar amino acids 
and mutation of the basic residues into alanines blocked the nuclear import of NM1. The 
NLS does not resemble to any of the NLSs already described in the literature and, thus, it 
might be expected to have some unique properties.  Similarly to NM1, also the neck of 
other unconventional myosin, myosin Vb, contains IQ sequence, that was shown to be 
responsible for nuclear and nucleolar localization of this myosin. Furthermore, it also 
mediates interaction with RNA pol I (Lindsay and McCaffrey, 2009). An IQ motif of 
another actin and PIP2 binding protein, the neural Wiskot-Aldrich syndrome protein (N-
WASP), serves as an NLS (Suetsugu and Takenawa, 2003). In conclusion, the ability to 
drive nuclear import appears to be common to various IQ motifs. 
7.2.2. Role of IQ2 in plasma membrane localization of NM1/Myo1c 
NM1/Myo1c neck-tail domain (NM1-(Q123.T)), was shown previously to associate with 
the plasma membrane through interaction with PIP2. This interaction was assigned to the 
putative PIP2-specific PH domain in the tail region of myo1c (Hokanson et al., 2006) 
and/or another less specific to the neck region (Hirono et al., 2004). Interestingly, NM1 
mutants which either lacked the second IQ motif or the basic residues within the second IQ 
sequence were misslocalized from the plasma membrane to the cytosol (Fig. 10B and 
10C). These data are in agreement with previously published work that identified the IQ2 
as additional plasma membrane binding site (Hirono et al., 2004). 
7.2.3. Mechanism of NM1 nuclear import 
The basic mechanism of NM1 nuclear import appears to involve karyopherins, because 
importin 5, importin 7 and importin-β1 were found to be associated with both 
overexpressed and endogenous NM1. The interaction of importin 5 with NM1 NLS seems 
to be specific since NM1 mutant lacking the basic amino acids in NLS did not bind this 
karyopherin. 
Canonical importin-mediated nuclear entry is controlled by the nuclear RanGTP which, 
upon binding to importins, releases their cargos. Surprisingly, the complex of NM1 with 
importin 5 is stable in the presence of RanGTP (Fig. 12E) and its nuclear import is rather 
dependent on the levels of calmodulin (Fig. 13B). This suggests that nuclear import of 
NM1 is mediated by a non-canonical pathway.  Indeed, such a calmodulin-dependent and 
Ran-independent nuclear import pathway has been shown to regulate the 
nucleocytoplasmic localization of several transcription factors (SOX9, SRY, c-Rel). The 
N-terminal domain of SRY and SOX9 contains a calmodulin-binding domain followed by 
an NLS (Harley et al., 1996). It was shown that calmodulin binding stimulates the nuclear 
entry of SRY and SOX9 (Argentaro et al., 2003; Sim et al., 2008). On the other hand the 
NF- B/Rel family protein c-Rel binds Ca2+-calmodulin via sequence near the NLS and this 
binding blocks its nuclear accumulation  (Antonsson et al., 2003). The NLS of NM1 
resides in close vicinity of the second IQ motif. We showed that IQ2 alone is able to drive 





IQ1 seems to play a key role in regulation of NM1 nuclear import (Fig. 13B). In presence 
of elevated levels of calmodulin, IQ1 mediated the inhibition of nuclear import (Fig. 13B) 
and it also substantially increased the binding of CaM the IQ2 (Fig 13D).  
On the other hand, the crystallographic (Houdusse et al., 2006) and biochemical studies 
have shown that calmodulin binds the IQ motifs of unconventional myosins in Ca2+-free 
state and that elevated Ca2+ dissociates calmodulin from the neck of Myo1c (Gillespie and 
Cyr, 2002). More recent study showed that in the absence of calcium, Ca2+-free calmodulin 
(apo-CaM) was bound to the IQ1 with highest affinity whereas in the presence of calcium 
IQ1 dissociated Ca2+-CaM most rapidly. Ca2+ - induced dissociation of calmodulin 
molecules from the neck increases ATPase rate and inhibits the motility of Myo1c 
(Manceva et al., 2007). We propose a scenario in which the calmodulin occupies the IQ12 
at low Ca2+ cellular levels preventing the importin from binding to NM1. The Ca2+ 
oscilations which occur during G1 phase of cell cycle (Kahl and Means, 2003) or which 
follow the signal transduction events (Yip et al., 2008) might cause the calmodulins to 
dissociate from the NM1 neck. As a result, the CaM-free IQ2 will subsequently bind to the 
import receptor that transports the NM1 to the nucleus. Taken together, at the cellular 
level, both the motor function of NM1/Myo1c and its localization appear to be dynamically 
regulated by transient changes in Ca2+ concentration. Obviously, further experiments are 
needed to reveal the details of the mechanism. 
7.2.4. Nuclear localization of NM1/Myo1c  
The fact that both Myo1c and NM1 contain the same NLS sequence points to the question 
whether also Myo1c would be present in the nucleus along with NM1. NM1 was first 
detected in the nucleus in 1997 (Nowak et al., 1997) using the antibody specific to N-
terminus of NM1. Myo1c has never been reported in the nucleus since the antibody 
directed to the C-terminus (Dumont et al., 2002) does not label the nuclei of cells. 
Intriguingly, upon transfection with either NM1 or Myo1c, the nuclear signal could be 
readily detected also by this antibody (Fig. 11B). One plausible explanation of this 
discrepancy would be that epitope is probably masked by nuclear binding partners or 
posttranslational modifications. However, the steady-steate cytosol to nucleus distribution 
of endogenous NM1 and Myo1c in mouse liver is approximately 70% (cytosol) to 30% 
(nucleus) Fig 10E. Therefore another possible intepretation is that the level of endogenous 




In conclusion, our work revealed a novel NLS sequence responsible for nuclear 
translocation of NM1. The fact that 16 N-terminal amino acids specific for NM1 are not 
involved in this process leads to an interesting question whether the two myosins serve the 
same functions in the nucleus and in the cytoplasm. Obviously, further investigation is 
needed to answer the question. 
7.3. Discussion part III -  Identification of novel NM1 interacting 
proteins 
Nuclear myosin 1 (NM1) is an isoform of myosin 1c (Myo1c), both are monomeric and 
belong to the class I unconventional myosins. Although the molecular structure of the two 
proteins seems to be very alike, the functions attributed to them differ. Here we further 
explored the localization, expression and binding partners of the two isoforms of the 
protein.  
7.3.1. NM1/Myo1c expression 
We found that localization of both myosins in a cell overlaps to a high degree. Both are 
localized in nucleus and cytoplasm. Surprisingly, we found that similar to Myo1c also 
NM1 is more cytoplasmic at steady state. This is in contrast to previously published data 
(Pestic-Dragovich et al., 2000; Fomproix and Percipalle, 2004) that described NM1 as the 
predominantly nuclear protein. Here we showed that the previous conclusion was based on 
the labeling with antibody that also cross-reacted with some other nuclear protein that 
contained a sequence partially overlapping with the NM1 N-terminal peptide. The 
distinctly nuclear localization was observed only in small number of cells after forced 
expression of the NM1 from a plasmid. On the other hand, cells that stably expressed 
tagged NM1, shoved predominantly cytosolic and plasma membrane localization. 
Although NM1 is not enriched in nucleus compared to cytoplasm, there are plenty of in 
vitro data that show the direct influence of NM1 on transcription machinery. This indicates 
that even low levels of this protein are sufficient to exert an effect. We observed previously 
the increased expression of NM1/Myo1c in lung tissue, and that the ratio between NM1 
and Myo1c is not the same in all tissues therefore, it could be regulated. Here we found 
that in lung about 43 % of total NM1/Myo1c comprises the NM1. Interestingly, similar 
results were observed in knock-in mice that harbored construct which contained genomic 
region 4 kilobases upstream the Myo1c start translation start codon  (Holt et al., 2002), 
without the more distal start of transcription (Pestic-Dragovich et al., 2000). In lungs, this 
construct yielded 35% of total Myo1c mRNA while the expression was higher (65%) in 
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inner ear. We could hypothesize that the genomic organization of NM1/Myo1c gene 
contains two separate promoters. The proximal one located upstream the exon -1 drives the 
expression of NM1 mRNA, and another one about 6 kb upstream close to the exon -2 
where the expression of Myo1c starts. 
7.3.2. NM1 associated proteins 
We re-inspected the NM1/Myo1c localization in the mouse tissues and found relatively 
high expression in epithelial and endothelial cells. We identified a number of proteins that 
associate with NM1 in the corresponding cell lines. Most of them were either actin or 
plasma membrane associated proteins. We do not know the functional meaning of the 
interactions with NM1. Nevertheless, based on high sequence similarity with Myo1c we 
could hypothesize that the NM1 takes part in the same cytosolic processes as Myo1c. 
Indeed, some of the identified proteins such as actinin 4, annexin II and protein kinase C 
alpha were also found to co-purify or co-localize with Myo1c. One extensively studied 
function of Myo1c is the mediation of mechanotransduction in the inner ear (Spinelli and 
Gillespie, 2009). Myo1c acts as dynamic linker between the plasma membrane and 
cytoskeleton that mechanically closes the ion channels and regulates the influx of calcium 
in response to mechanical stimulus. One possibility is that similarly to Myo1c, NM1 links 
the membrane to underlining cytoskeleton and is also involved in sensing the mechanical 
stimuli. But how does mechanical stress of plasma membrane relate to the transcription? 
Interestingly, it was shown recently that human periotodontal fibroblasts responded to 
mechanical stretching by attenuation of transcription. Moreover, the investigators also 
observed the relocalization of NM1 from the nucleus to cytoplasm (Steinberg et al., 2011). 
This suggests indirectly that NM1 could be involved in response to mechanical stress, but 
the details of how remain to be solved. 
As shown initially, NM1 influenced transcription also in unstressed cells. The acute 
depletion of NM1/Myo1c in HeLa cells leads to a decreased transcription rate, while 
overexpression of NM1 stimulated the transcription (Philimonenko et al., 2004). Besides 
the direct influence of NM1 on transcription apparatus (Hofmann et al., 2006b), the 
observed changes in transcription could be explained by the cytosolic/plasma membrane 
activities of NM1. In adipocytes, the Myo1c isoform associates with Rictor (Rapamycin 
insensitive companion of mTOR) that interacts with the mammalian target of rapamacin 
mTOR. The mTOR kinase is a major controller of cellular proliferation and growth, which 
partially exerts its function thru a regulation of RNA polymerase I transcription (Grummt, 
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2003). Myo1c also facilitates the membrane insertion of a solute carrier protein SLC2A4 
which is a glucose importer also known as GLUT4. Interestingly, here we found SLC3A2 
as one of proteins that associated with NM1. SLC3A2 comprises the heavy subunits of the 
large neutral amino acid transporter (LAT1) that is also known as CD98. LAT1 is 
responsible for the intracellular transport of neutral branched (valine, leucine, isoleucine) 
and aromatic (tryptophan, tyrosine) amino acids. Interestingly, it was shown previously 
that leucine is an activator of mTOR (Lynch, 2001). Therefore one attractive hypothesis 
would be that NM1 regulates a membrane insertion of SLC3A2 which leads to an 
increased import of leucine that in turn activates mTOR and cell growth. The other way 
around, the acute depletion of NM1/Myo1c by RNAi leads to a decreased import of 
leucine and hence lower mTOR activity. It is of interest that similarly to NM1/Myo1c, 
LAT1 is highly expressed in endothelial cells. Nevertheless, the presented mechanism is 
entirely hypothetical and requires substantially more work to prove. 
In podocytes, Myo1c facilitated the membrane integration of Neph1 and was implied in 
maturation of cell-cell junctions (Arif et al., 2011). To support the hypothesis of functional 
similarity between NM1 and Myo1c, we found Catenin delta-1 (CTNND1), a member of 
Armadillo protein family, which functions in adhesion between cells and in signal 
transduction (Hartsock and Nelson, 2008), and Receptor-type tyrosine-protein phosphatase 
F interacting protein 1 (Liprin 1) as proteins that associate with NM1 in digitonin extracts 
of HeLa cells. Altogether we could hypothesize that in cytosol, NM1 could act in the same 
processes as Myo1c but associates with different proteins than Myo1c. This could cause 
slight differences in the localization pattern of NM1 and Myo1c. As a results we do not see 











NM1 was the first myosin protein identified in the cell nucleus in 1997. As a 
predominantly nuclear protein, NM1 was shown to have function in transcription by RNA 
polymerases I and II by us (Hofmann et al., 2006b; Philimonenko et al., 2004) and others 
(Fomproix and Percipalle, 2004). On the other hand, the cytoplasmic, or more exactly the 
plasma membrane myosin 1c was discovered in 1992. These two proteins are the product 
of one gene. The only difference between NM1 and Myo1c are the 16 amino acids at the 
N-terminus of NM1. Based on different cellular localization of NM1 and Myo1c, previous 
publications considered the NM1 molecule to be a nuclear protein that is functionally 
distinct from its cytoplasmic isoform, the Myo1c. In simple words, however, one can say 
that NM1 is composed of Myo1c +16 amino acids. In this simplistic view, one obvious 
question popped up. What is the N-terminal piece changing in Myo1c molecule to such an 
extent that it becomes NM1? The attempt to answer this rather simple question led to the 
discovery of a number of interesting facts some of which are provocative and prompted us 
to re-visit or re-interpret the some of the previous data. 
The broad expression of NM1 in various mouse tissues strongly suggested that it could 
serve some important function. In addition to that, the relatively high conservation of N-
terminus among vertebrates implied that it might contribute to some important property 
that was preserved during evolution. Therefore, the next question was whether this 
preserved property was the ability to localize the myosin molecule into the nucleus. In 
contrast to some previous data, we found that the N-terminus itself is not an NLS. 
Moreover, the “cytoplasmic” Myo1c molecule did localize into nucleus even without N-
terminal extension. Subsequently, we found that the nuclear translocation is driven by 
another sequence that is shared by NM1/Myo1c. Importantly, the highly overlapping 
distribution of endogenous NM1 and Myo1c in a cell strongly suggested that the N-
terminus does not contribute to the cellular localization of the isoforms. Thus its function 
could be in changing some of the molecular properties of NM1. The attachment of N-
terminus to head could influence the binding of myosin to actin or the myosin ATPase 
cycle. Therefore, the next question was whether Myo1c could serve the same functions as 
NM1. To answer this, we made one simple experiment in which we depleted both proteins 
and added back only Myo1c. The result suggested that the myosin isoforms could be 
functionally equal. Another independent notion that supported this hypothesis was the fact 
that neither the mice nor the fibroblasts derived from NM1 knockout mice displayed any 
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severe defect in transcription (Venit et al., in preparation). Since the NM1 is not expressed 
in this mouse, we could hypothesize that the Myo1c is able to replace NM1 functionally. 
This could be true especially in tissues where the expression of NM1 is not predominant or 
the lack of one isoform is compensated by another. On the other hand, NM1/Myo1c is 
highly expressed in cell types that face mechanical tension or fluid shear stress. Therefore, 
to unmask the possible defect in the NM1- lacking cells, one would have to compare the 
behavior of KO and WT cells under stress conditions.  
Of importance was also the finding that at steady state, NM1 is not predominantly nuclear. 
This statement is supported by number of observations presented in the last chapter of this 
thesis. Along with Myo1c, NM1 is localized predominantly in the cytoplasm and at the 
plasma membrane. None of the previous work describing the functions of Myo1c in 
cytosol took this into an account, and by depleting Myo1c the investigators were also 
reducing the level of NM1. Therefore, some of the cytosolic functions of Myo1c could be 
attributed to NM1. Indeed, we identified a large number of cytosolic or cytoplasmic 
membrane associated proteins as the proteins that co-purify with cellular NM1. Therefore, 
in addition to the “nuclear” functions NM1 could play a role in the cytoplasmic processes. 
On the other hand, since the Myo1c could localize to the nucleus, it could also play a role 
in transcription.  
Myo1c has an interesting molecular property. It could act as a molecular ratchet allowing 
the attached cargo to move in one direction only. The promoter-proximal pausing of RNA 
polymerase (RNAP) is a divergent (anti-sense) transcription (Core et al., 2008) known as 
bidirectional expression of short transcripts (BEST). It was shown to be a general feature 
of RNA polymerase transcription in mammalian tissues (Seila et al., 2008). Remarkably, 
the data available so far show that NM1 motor activity is needed during the early stages of 
transcription initiation (Hofmann et al., 2006b; Ye et al., 2008). Therefore, in a hypothetic 
scenario the NM1/Myo1c together with actin could form a molecular motor that would act 
as enhancer of transcription by helping the RNAP to maintain the directionality of 
transcription.  Unfortunately we have only sparse data so far to be able to show it. 
Nevertheless, the fact that acute depletion of NM1/Myo1c leads to both the reduction of 
Pol I transcription and proliferation rate suggests that NM1/Myo1c could be involved in 




9.1. What is the expression and localization pattern of NM1 in mouse 
tissues?  
We demonstrated that NM1 is present in cell nuclei of all mouse tissues examined except 
for cells in terminal stages of spermatogenesis. Quantitative PCR and western blots 
demonstrate that the expression of NM1 in tissues varies, with the highest levels in the 
lungs. The expression of NM1 is lower in serum-starved cells and it increases after serum 
stimulation. The lifespan of NM1 is longer than 16 h as determined by cycloheximide 
translation block. A homologous protein is expressed in human, chicken, Xenopus, and 
zebrafish, as shown by RACE analysis. The analysis of genomic sequences indicates that 
almost identical homologous NM1 genes are expressed in mammals, and similar NM1 
genes in vertebrates. 
9.2. Which NM1 domain is responsible for the nuclear localization of 
the protein? 
We investigated the mechanism of nuclear import of NM1 in detail. Using overexpressed 
GFP chimeras encoding for truncated NM1 mutants, we identified a specific sequence that 
is necessary for its import to the nucleus. This novel nuclear localization sequence is 
placed within calmodulin-binding motif of NM1, thus it is present also in the Myo1c. We 
confirmed the presence of both isoforms in the nucleus by transfection of tagged NM1 and 
Myo1c constructs into cultured cells, and also by showing the presence of the endogenous 
Myo1c in purified nuclei of cells derived from knock-out mice lacking NM1. Using pull-
down and co-immunoprecipitation assays, we identified importin beta, importin 5 and 
importin 7 as nuclear transport receptors that bind NM1. 
Since the NLS sequence of NM1 lies within the region that also binds calmodulin we 
tested the influence of calmodulin on the localization of NM1. The presence of elevated 
levels of calmodulin interfered with nuclear localization of tagged NM1. We have shown 
that the novel specific NLS brings not only the "nuclear" isoform of myosin I (NM1 
protein) but also its "cytoplasmic" isoform (Myo1c protein) to the cell nucleus. This opens 
a new field for exploring functions of this molecular motor in nuclear processes, and for 
exploring the signals between cytoplasm and the nucleus 
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9.3. What is the composition of protein complexes containing NM1? 
Since NM1 is distributed in nucleus and also in cytoplasm, we sought to identify all 
possible cellular proteins that could interact with NM1. Using co-immunoprecipitation and 
mass spectrometry we identified a large number of proteins that associate with NM1 in the 
cellular extracts of various human cell lines and mouse lungs. Most of the identified 
proteins were actin and plasma membrane associated. These proteins are involved in 
mechanical stabilization of cell cytoskeleton, exocytosis and cell-cell contacts. We found 
that NM1/Myo1c colocalizes with selected proteins mainly at the leading edge of plasma 
membranes and cell-cell contacts. Thus, similarly to Myo1c, NM1 could also play an 

















NM1 was detected using rabbit polyclonal antibody directed to N-terminal part of NM1 
(M3456, Sigma). Polyclonal antibody R2652 and monoclonal antibody mT2 against the 
tail of Myo1c was a gift from Peter G. Gillespie, Oregon Hearing Research Center and 
Vollum Institute (Gillespie et al., 1993; Dumont et al., 2002). Antibodies against β-actin 
(A2066) and γ-tubulin (T6557) were purchased from Sigma; antibody against GAPDH 
(clone 6G5) is available from Acris. In immunofluorescence and co-immunoprecipitation 
experiments we used affinity purified antibody directed to the NM1 N-terminus M3567 
(Sigma), antibodies to lamin B (M-20, Santa Cruz Biotechnology), V5-tag (Serotec), V5-
tag (V8137-Sigma), FLAG-tag (Stratagene) and to calmodulin (Upstate, cat. No.  05-173). 
Anti-importin 5 (sc-17802), importin beta (sc-1919) and importin 7 (sc-55235) were 
purchased from Santa Cruz Biotechnology; rabbit polyclonal anti-NM1 for western blots 
and immunofluorescence in Experimental Part III was kindly provided by Piergiorgio 
Percipalle (Fomproix and Percipalle, 2004), and EGFP antibody was purchased from 
Invitrogen (cat. No. A11122). R5 antibody (Exbio Antibodies) was generated against N-
terminal peptide of NM1 (AA1-15), serum was affinity purified on the same peptide. We 
also used monoclonal antibodies to Filamin A (MAB1678, Cheminon); Annexin II (BD 
Pharmingen™); Lamin A (clone 133A2, kind gift from Yves Raymond); and  a polyclonal 
anti Myosin 1B (HPA013607). 
10.2. Cells and serum activation 
NIH 3T3 and HeLa cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal calf serum (FCS) and antibiotics in humidified 5% CO2/air, 
37°C environment. The protocol for serum activation experiments was essentially as 
described (Iyer et al., 1999). Briefly, NIH 3T3 cells were grown on six-well plates. When 
they reached approximately 50% confluence they were washed two times with phosphate 
buffered saline (PBS), and low serum medium (0.1% FCS) was added to the plates. The 
cells did not show morphological signs of apoptosis under these conditions. After 48 h, the 
medium was replaced with a fresh medium containing 10% FCS. Cells were harvested 
before the addition of serum (time 0) and after 2, 4, 8, and 16 h of serum stimulation.  
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10.3. Cells and transfections 
Cell lines cells were obtained from American Type Culture Collection. NIH/3T3 (ATCC 
No. CRL-1658), U2OS (ATCC No. HTB-96), HeLa (ATCC No. CCL-2) and HEK 
293T/17 (ATCC No CRL-11268) were kept in DMEM supplemented with 10% fetal 
bovine serum (FBS) in 5% CO2/air, 37°C, in humidified atmosphere. HeLa S3 (ATCC 
No.CCL-2.2) were kept in S-MEM supplemented with 5% FBS and grown in spinner 
flasks. The U2OS cells were transfected with FUGENE 6 (Roche) according to the 
manufacturer’s protocol, fixed after 48 h and either observed directly under the microscope 
or labeled with antibodies. HEK293T cells were electroporated using GenePulser (Biorad) 
electroporator as described (Galvez et al., 2001). The efficiency of electroporation was 
about 90%. 
10.4. Cell synchronization  
U2OS cells were treated with nocodazole (80 ng/ml or 400 ng/ml) for 16h. Mitotic cells 
were washed off the dish with medium, spun down and resuspended in fresh medium, and 
seeded on coverslips. Cells on coverslips were cultivated further in fresh medium and fixed 
2,4,6,8, and 10 hours after the nocodazole block. Aphidicolin (1 μg/ml) was applied for 16 
hours, cells were washed, cultivated in fresh medium, and then fixed 2, 7, 11, 17, and 22 
hours post aphidicolin block. NIH 3T3 cells were synchronized by mitotic shake-off. 
Harvested cells were seeded on poly-lysine coated coverslips, and allowed to attach for 15 
min. HeLa cells, used for co-immunoprecipitation of endogenous NM1, were incubated for 
16 hours with nocodazole (400 ng/ml), washed in PBS, and then cultivated in complete 
medium for additional 3 h prior to the harvest. 
10.5. Plasmid DNA preparation  
NM1-GFP, GFP-NM1, Myo1c-GFP, NM1-V5, Myo1c-V5 were obtained by ligation of 
full length mouse NM1 (amino acids 1-1024) and Myo1c (aa 1-1028) (Pestic-Dragovich et 
al., 2000) cDNA into pEGFP-C3, pEGFP-N3 (Clontech) and pcDNA3.1/V5-His 
(Invitrogen) vectors. Truncations containing head (H) neck with IQ domains (Q123) and 
tail (T) domains were generated using inverse PCR.  NM1-V5-(H) (aa 1 to 716) was 
generated from NM1-V5.GFP-NM1-(Q123.T) (aa 712 to 1044),GFP-NM1-(Q3.T) (aa 763 
to 1044), GFP-NM1-(Q123.T -Δ853) (aa 712 to 853), GFP-NM1-(Q12) (aa 712 to 770) 
were constructed from GFP-NM1 using standard cloning methods. For inspection of NLS-
peptide localization, we produced a testing construct GFP-PK that contains in-frame fusion 
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of EGFP and cytosolic enzyme pyruvate kinase (PK) (Frangioni and Neel, 1993), GFP-PK-
IQ-12 was produced by ligation NM1-(Q12)  sequence into GFP-PK vector. GFP-PK-IQ1 
(aa 712 to 740), GFP-PK-IQ2 (aa 739 to 766) GFP-PK-NLS (NM1) (aa 754 to 766) were 
generated by PCR deletions from GFP-PK-IQ1,2. Nt-GFP-PK was produced by ligation of 
NM1 N-terminal sequence (aa 1-16) in front of EGFP in GFP-PK vector.  Ligation of the 
OneStrep tag sequence (IBA) in front of EGFP in the pEGFP-C3 vector generated Str-
GFP. Str-GFP-NM1-(Q123.T) was produced by ligating the Q123.T (aa 712 to 1044) 
sequence into Str-GFP vector. Calmodulin cDNA was prepared from HeLa total cell RNA 
using RT-PCR and cloned into pcDNA3.1 vector (Invitrogen). Bacterial expression vector 
pET-Str-His was generated by ligation of OneStrep sequence into the pET28b vector 
(Novagen). Str-IQ12-His was produced by an in-frame ligation of the PCR-amplified 
fragment of NM1-(Q12) (aa 712 to 770) between the OneStrep- and His-tag. Point 
mutations in the NLS sequence of NM1 were generated by the site directed mutagenesis 
protocol (Stratagene). Bacterial expression plasmid pQE-RanQ69L was kindly provided by 
Prof. Dirk Görlich. Detailed description of all cloning procedures is available upon request. 
Recombinant proteins were expressed in bacteria and purified using Ni-NTA agarose 
column as described (Kutay et al., 1997; Manceva et al., 2007). 
10.6. Animals 
Laboratory mice strain C53/Bl6, four males and three females, 10–16 weeks old were 
killed by cervical dislocation. Samples of the small intestine, pancreas, brain, kidney, skin, 
heart muscle, testis/ovary, striated muscle, spleen, liver, and lungs intended for RNA 
isolation were stored in RNAlater storage solution (Sigma), parts of the tissues intended for 
subsequent cryostat slicing were frozen in liquid nitrogen. Experiments were performed 
according to the national and local regulations for use of experimental animals.  
10.7. Immunofluorescence microscopy 
For immunostaining in Experimental part I, 6 μm cryostat sections were mounted onto 
glass slides coated with poly-L-lysine, and fixed 15 min in absolute ethanol at room 
temperature. Sections were then permeabilized in 0.2% Triton X-100 in PBS for 10 min, 
incubated with antibody against NM1 (16 μg/ml, 1 h at RT), and with FITC-conjugated 
goat anti rabbit secondary antibody (Jackson ImmunoResearch). Coverslips were mounted 
with Mowiol (Sigma) containing DABCO (Sigma) as an antifading agent, 0.5 μg/ml 
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propidium iodide, and 0.1 μg/ml DAPI (Sigma), and observed with confocal microscope 
Leica TCS SP.  
Mouse tissues experimental part III were obtained from mouse fixed  by whole body 
perfusion with  4% PFA in PBS. Tissues excised from the body were further fixed using 
4% PFA in PBS over night and dehydrated in sucrose. After freezing in mounting media, 
7-10 µm sections were prepared using cryostat. Cryostat sections on slides were incubated 
3x5 min with 0.1% sodium borohydride, washed, permeabilised with 0.1% PBS, blocked 
with 5% BSA, washed 3x in PBS/TWEEN and incubated with indicated antibodies for 1h 
at room temperature. Signal from primary antibodies was visualize using ALEXA 647 
conjugated goat anti rabbit antibody. 
In experimental parts II and III 
Cells grown on coverslips were fixed with freshly prepared 3% formaldehyde for 10 
minutes, permeabilized with 0.1%  Triton X-100 in PBS for 10 minutes, incubated with 
primary antibodies for 1 hour at room temperature. To unmask epitopes for actin, actinin 
and annexin II, cells in Fig.20 were fixed with -20°C metanol, re-hydrated in PBS/Tween 
and incubated with primary antibodies diluted in PBS containing 0.05% Tween-20 (PBST) 
After washing in PBST, coverslips were incubated with ALEXA 488  or ALEXA 647 goat 
anti-rabbit or goat anti-mouse secondary antibodies (Invitrogen). Coverslips were mounted 
with Mowiol (Sigma) containing DABCO (Sigma) as an anti-fading agent and 0.1 µg/ml 
DAPI (Sigma), and observed under fluorescent or confocal microcopes (LEICA DM 6000, 
LEICA DMI 6000, LEICA TCS SP5 AOBS TANDEM). Brightness and contrast of 
captured digital images was adjusted with Photoshop software (Adobe). 
10.8. Immunoblots 
Tissues and cells for the experiments on Figs. 2,5 and 18 were homogenized in SDS lysis 
buffer (60 mM Tris pH 6.8, 10% glycerol, 2% SDS), lysates were cleared by centrifugation 
and total protein content was measured using BCA assay (Pierce). In other experiments, 
cultured cells were lysed in lysis buffer (20 mM Tris pH 7.4, 200 mM NaCl, 1% Triton X-
100, 2 mM EDTA, 10 mM EGTA, 10 mM K2HPO4, 1 mM PMSF, 10 μg/ml leupeptin, 
1 μg/ml pepstatin), briefly sonicated, and cleared by centrifugation. Protein content was 
measured by Bradford assay (Biorad) of  BCA (Pierce). Equal amounts of protein were 
loaded on 8% gel, proteins were separated by SDS-PAGE and transferred to nitrocellulose 
membrane. The blots were incubated with antibodies, horseradish peroxidase conjugated 
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secondary antibodies (Bio-Rad), and the signal was visualized by ECL (Pierce). Where 
indicated, signal from primary antibodies was visualized using fluorescently conjugated 
antibodies on an Li-cor Odyssey imaging system.  
The two myosin isoforms were separated according to (Rossini et al., 1995) with following 
modifications. We used a 0.75 mm thick midigel format (Hoefer SE 600 Ruby), 4% 
stacking gel (15 mm high) and 8% resolving gel. Both gels contained 30% glycerol. 
Electrophoresis was run for 14 h with maximum power 3 W, maximum voltage 350 V, and 
with cooling to 8°C by circulator bath.  
10.9. RNA isolation and RT-qPCR 
Total RNA from cells and tissues was isolated with TriReagent (Sigma) according to 
manufacturer’s protocol. The cells were lysed on plates. Concentration of RNA was 
measured by spectrophotometry and the integrity of RNA was checked on denaturing 
agarose gel. A total of 100 ng of RNA was reverse-transcribed with random hexamers as 
primers using TaqMan Reverse Transcription Reagents (Applied Biosystems). Real-time 
qPCR was performed in ABI Prism 7300 instrument using SYBR Green PCR Master Mix 
(all Applied Biosystems). The following primers were used: mouse NM1 
CGGCAGGATGCGCTACC and TCAAGGCGCTCTCCATGG, mouse ß-actin 
GCCCTGAGGCTCTTTTCCA and TGCCACAGGATTCCATACCC, and mouse 
GAPDH GGAAGGGCTCATGACCACAG and GCCATCCACAGTCTTCTGGG. Data 
were evaluated with 2-ΔΔ CT method (Livak and Schmittgen, 2001) using control genes as 
described in Results.  
10.10. RACE 
RLM-RACE (RNA ligase-mediated rapid amplification of cDNA ends) was performed 
according to the protocol developed by Invitrogen with minor modifications. Briefly, total 
RNA was first treated with Shrimp Alkaline Phosphatase (SAP) to remove 5′ phosphates 
from all uncapped RNAs. RNA was then extracted by phenol:chloroform and treated with 
Tobacco Acid Pyrophosphatase to remove the cap, yielding 5′ phosphate. After 
phenol:chloroform extraction, a special RNA adapter oligonucleotide was ligated to 5′ 
phosphorylated RNAs by T4 RNA Ligase. RNA was extracted once more and reverse-
transcribed with random hexamers as primers using TaqMan Reverse Transcription 
Reagents (Applied Biosystems). PCR was performed as above with touchdown protocol. 
(Annealing temperature went down every five cycles from 70° to 68°, 65°, and then 
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remained 63° during the rest of amplification.) Primers were designed to align with 
homologues of Myo1c in the respective species: human MYO1C (GenBank NM_033375) 
GTGTCCGCCACGGCAAACAGG and CCGTGCGCAGTGCTCGGTACAC, chicken 
MYO1C (GenBank NM_001006220) TCACTGGTGAAGTTCTCAAGCAGG, Xenopus 
laevis MYO1C (GenBank BC044718) TCTTTATATGGGTTGACAGAGACC and 
GCTTCACTTGTATAGTTTTCCAACAG, and Danio rerio Myo1c homologues GenBank 
XM_690832 ATGAAAGCGGCTTCACTGTTGTGG and GenBank XM_689729 
GACAAAATCCTGCACACCCACCC. PCR products were separated on 3% agarose gel, 
bands were excided, isolated by Zymoclean Gel DNA Recovery Kit (Zymo Research), and 
sequenced on ABI Prism 3100 (Applied Biosystems).  
10.11. Sequence searches, alignment, and construction of phylogenetic 
trees 
The sequences similar to NM1 were found in the GenBank and Ensembl databases using 
TBLASTN (Altschul et al., 1997). Genscan (Burge and Karlin., 1997) was used for gene 
predictions in genomic DNA. Sequences were aligned with ClustalW and manually 
refined. The phylogenetic trees were constructed and bootstrap tested by minimum 
evolution method using molecular evolutionary genetics analysis software MEGA version 
3.1 (Kumar et al. 2004).  
10.12. Pull-down assays and immunoprecipitation 
Digitonin extract from suspension HeLa cells, prepared as described (Kutay et al., 1998), 
was diluted to 2 mg/ml of total protein in lysis buffer (50 mM HEPES pH 7.4, 150 mM 
NaCl, 75 mM potassium acetate, 5 mM magnesium acetate, 1 mM DTT, protease 
inhibitors). After dilution, purified bacterially expressed Str-IQ12-His was added to the 
lysate. After 3 hours of incubation, the extract was centrifuged to remove precipitated 
proteins and supernatant was further incubated for 1 hour with StrepTactin Beads (IBA) to 
capture the bait and associated proteins. Beads were briefly washed 3 times with 1 ml of 
the lysis buffer followed by brief wash with IBA wash buffer (100 mM Tris pH 7.5, 100 
mM NaCl, 1 mM EDTA) and captured proteins were eluted from beads with the wash 
buffer supplemented with 2 mM biotin. HEK 293T cells electroporated with Str-GFP-
NM1-(Q123.T) or Str-GFP were collected by trypsinization into serum-containing 
medium. After centrifugation 300 g / 3 minutes, the cells were washed twice with ice-cold 
PBS and extracted twice with lysis buffer containing 50 mM HEPES pH 7.4, 150 mM 
potassium acetate, 5 mM magnesium acetate, 1 mM DTT, 1 mg/ml digitonin (Fluka), 
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EDTA-free COMPLETE inhibitors (Roche). After 4 hours of incubation with StrepTactin 
resin, the captured protein complexes were washed briefly 3 times with 1 ml of the lysis 
buffer followed by wash with 1 ml of IBA wash buffer. Proteins were eluted from beads 
with 2 mM biotin added into the wash buffer. The experiments with RanQ69L mutant were 
performed as described above, with the exception that after the 3rd wash a half of the beads 
was incubated for 10 min with buffer containing recombinant RanQ69L and the other half 
was incubated only in buffer. Elution with Ran mutant was repeated twice and remaining 
proteins were eluted from beads with IBA elution buffer containing 2 mM biotin. Eluates 
were concentrated ultrafiltration (Ultracel 10K, Milipore) and resolved on 6-20% gradient 
polyacrylamide gel.  
Endogenous NM1 was immunoprecipitated from adherent HeLa cells synchronized with 
nocodazole. Cells were extracted twice in lysis buffer (50 mM HEPES pH 7.4, 150 mM 
NaCl, 75 mM potassium acetate, 5 mM magnesium acetate, 1 mM DTT, 1mg/ml of 
digitonin and protease inhibitors), lysates were clarified by centrifugation (10 min, 16 
000g, 4°C), and incubated with beads containing either covalently bound antibody 
antibody to NM1 (Sigma, cat no M3567) or to EGFP (Exbio, Czech Republic, cat no 11-
473-C100). After 3 washes in 1 ml of lysis buffer beads were washed in 1ml of 50 mM 
amonium bicarbonate pH 7.5 to remove salts and detergent. Bound proteins were eluted 
twice with 500 µl of 500 mM amonium hydroxide. Eluates were evaporated using 
SpeedVac concentrator (Savant, Holbrook, NY, USA), dry pellets were  resuspended in 20 
ul of 1x SDS loading buffer, boiled and resolved on 6-20% gradient SDS PAGE. After 
transfer to nitrocelulose proteins were visualized using specific antibodies.  
GFP-PK constructs in Fig.13D were immunoprecipitated from lysates of electroporated 
HEK23T cells as follows. Cells were harvested by trypsinization, washed in PBS and lysed 
in lysis buffer (150 mM NaCl, 50mM Tris-HCL pH-7.5, 10mM EGTA, 2mM EDTA, 1% 
Triton X-100, protease inhibitors ROCHE). After clarification by centrifugation (10 min, 
16 000g, 4°C), supernatans were incubated with 20 µl of GFP-trap magnetic particles 
(ChromoTek GmbH, Germany). After 5 washes in 1 ml of lysis buffer particles were 
washed in 1ml of 50 mM amonium bicarbonate pH 7.5 to remove salts and detergent. 
Bound proteins were eluted  twice with 500 µl of 500 mM amonium hydroxide. Eluates 
were evaporated using SpeedVac concentrator (Savant, Holbrook, NY, USA), dry pellets 
were resuspended in 20 ul of 1x SDS loading buffer, boiled and resolved on 6-20% 
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gradient SDS PAGE. After transfer to nitrocelulose proteins were visualized using specific 
antibodies.  
In experimental Part III  
Cells were extracted in either in buffer containing 20 mM Tris pH 7.4, 150 mM NaCl, 1% 
Triton X-100, 2 mM EDTA, 10 mM EGTA, 10 mM K2HPO4 (Triton extraction buffer), or 
20 mM Tris pH 7.4, 150 mM potassium acetate, 5 mM magnesium acetate, 1 mM DTT, 1 
mg/ml digitonin (digitonin buffer) complete protease inhibitors (ROCHE), 20 mM Tris pH 
7.4, 150 mM potassium acetate, 5 mM MgCl2, 1 mM DTT, 0.1% Tween 20, protease and 
phophatase inhibitors (Tween buffer). Cells were disrupted by sonication on ice. Lysates 
were cleared by centrifugation 14000g/10min/4°C. After 5 washes in 1 ml of lysis buffer 
particles were washed in 1ml of 50 mM amonium bicarbonate pH 7.5 to remove salts and 
detergent. Bound proteins were eluted twice with 500 µl of 500 mM amonium hydroxide. 
Eluates were evaporated using SpeedVac concentrator (Savant, Holbrook, NY, USA), dry 
pellets were resuspended in 20 ul of 1x SDS loading buffer, boiled and resolved on 6-20% 
gradient SDS PAGE. 
10.13. Proteolytic digestion and sample preparation 
Protein bands were cut from the gel, sliced into the small pieces, and decolorized in sonic 
bath at 60°C several times with 0.1 M 4-ethylmorpholine acetate (pH 8.1) in 50% 
acetonitrile (ACN).  After complete destaining, proteins were reduced by 50mM TCEP in 
0.1 M 4-ethylmorpholine acetate (pH 8.1) for 5min at 80°C and alkylated using 50mM 
iodoacetamide in 0.1 M 4-ethylmorpholine acetate (pH 8.1) for 30min in dark at room 
temperature.  Then, the gel was washed with water, shrunk by dehydration with ACN and 
reswollen in water.  The rehydratation and dehydration of the gel was repeated twice.  
Next, the gel was reswollen in 0.05 M 4-ethylmorpholine acetate (pH 8.1) in 50% 
acetonitrile (ACN) and then the gel was partly dried using a SpeedVac concentrator 
(Savant, Holbrook, NY, USA).  Finally, the gel was reconstituted with cleavage buffer 
containing 0.01% 2-mercaptoethanol, 0.05 M 4-ethylmorpholine acetate (pH 8.1), 10 % 
ACN, and sequencing grade trypsin (Promega, 10 ng/μl).  Digestion was carried out 
overnight at 37 °C; the resulting peptides were extracted with 30% ACN/0.1% TFA and 
subjected to mass spectrometric analysis. 
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10.14. Mass spectrometric analysis 
Mass spectra were acquired in the positive ion mode on a MALDI-FTMS APEX-Ultra 
(Bruker Daltonics, Bremen, Germany) equipped with 9.4 T superconducting magnet and 
SmartBeam laser.  The acquisition mass range was 700 - 3500 m/z and 512k data points 
were collected.  A 280 V potential was applied on the MALDI plate.  The cell was opened 
for 2500 ms, 4 experiments were collected for one spectrum where one experiment 
corresponds to 300 laser shots.  The instrument was externally calibrated using PepMix II 
peptide standard (Bruker Daltonics, Bremen, Germany).  It results in typical mass accuracy 
below 2 ppm.  A saturated solution of α-cyano-4-hydroxy-cinnamic acid in 50% 
ACN/0.2% TFA was used as a MALDI matrix.  A 1 μl of matrix solution was mixed with 
a 1 μl of the sample on the target and the droplet was allowed to dry at ambient 
temperature.  After the analysis the spectra were apodized using square sin apodization 
with one zero fill.  The interpretation of mass spectra was done using DataAnalysis version 
3.4 and BioTools 3.2 software packages (Bruker Daltonics, Billerica, MA).  Proteins were 
identified by peptide mass fingerprinting (PMF) using a search algorithm MASCOT 
(Matrix Science). 
10.15. Generation of the NM1 knock-out mice 
To generate NM1-KO mice, loxP-recombination sites were introduced into NM1 gene by 
homologous recombination in R1 embryonic stem cell line (Nagy et al., 1993). Cre-
mediated recombination in germline cells, achieved by cross breeding with the meu-cre 
expressing mice (Leneuve et al., 2003) resulted in removal of the loxP-flanked exon-1 
from the mouse NM1 genomic sequence (sequence from -165 to + 116 base pairs from 
NM1 translation initiation site). In the mutant NM1 allele, only the start codon initiating 
the translation of Myo1c is present. As a result, only Myo1c protein is expressed in all 
tissues. Mice were genotyped using genomic PCR, and the absence of NM1 protein was 
confirmed by Western blotting (Venit et al., in preparation). 
10.16. Isolation of nuclei from mouse liver 
Nuclei from mouse liver were isolated as described (Nagata et al., 2010). Briefly, mice 
were killed by CO2 and liver was homogenized in ice-cold buffer A (250 mM sucrose, 5 
mM MgCl2, 10 mM HEPES  pH 8) in glass Dounce homogenizer. The homogenate was 
spun down (600 g/10 min), the supernatant was taken as the cytosolic fraction and the 
pellet was washed once in buffer A. The crude nuclear pellet was resuspended in buffer B 
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(2.0 M sucrose, 1.5 mM MgCl2, 10 mM HEPES pH 8) and centrifuged 30 minutes/16000 
g. Purified nuclei were resuspended in buffer Z (62.5 mM Tris pH 6.8, 10% glycerol, 2% 
SDS), heated to 90 °C for 10 minutes, sonicated, and centrifuged again (16000 g/10 min). 
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